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Molecular alterations in the phosphatidylinositol 3-kinase (PI3K)/ 
serine/threonine protein kinase B (AKT) signaling pathway occur frequently in 
estrogen receptor–positive (ER-positive) breast tumors. Patients with ER-positive, 
human epidermal growth factor receptor 2–negative (HER2-negative) metastatic 
breast cancer are often treated with cyclin-dependent kinase (CDK4/6) inhibitors 
such as palbociclib in combination with endocrine therapy. Although this is a very 
effective regimen, disease progression ultimately occurs in most patients. Further, 
the modulators of palbociclib sensitivity remain unclear. The purpose of this study 
was to identify synthetic lethality partners that can enhance palbociclib’s antitumor 
efficacy in ER-positive breast cancer with PI3K pathway alterations. 
Using ER-positive isogenic breast cancer cell lines, we demonstrated that the 
efficacy of palbociclib is attenuated in the presence of PIK3CA or AKT1 mutations. 
Using a shRNA library screen targeting cancer–related human kinases, we identified 
that downregulation of discoidin domain receptor 1 (DDR1), a tyrosine kinase active 
in various cancers, is synthetically lethal with palbociclib. DDR1 knockdown by 
shRNA markedly reduced the growth of PIK3CA and AKT1 mutant and wild-type 
(WT) ER-positive cell lines in vitro. In addition, DDR1 pharmacological inhibitor, 7rh 
vi 
 
benzamide, decreased cell growth and inhibited cell cycle progression in all cell 
lines, while selectively enhancing the sensitivity of PIK3CA and AKT1 mutant cells to 
palbociclib. Combined treatment of palbociclib and 7rh further induced cell cycle 
arrest, decreasing PLK1, cyclin E2, and RB phosphorylation in PIK3CA and AKT1 
mutant cell lines. In vivo, 7rh significantly enhanced the antitumor efficacy of 
palbociclib. Similarly, reverse phase protein array (RPPA) analysis of the xenografts 
revealed a greater PLK1 reduction in a combined 7rh and palbociclib treatment 
group. Our data indicate that DDR1 inhibition can augment the cell cycle 
suppressive effect of palbociclib and could be an effective targeted therapy for ER-
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CHAPTER 1:  INTRODUCTION 
CHAPTER 1: INTRODUCTION 
 
1.1 Breast cancer 
1.1.1 Breast cancer epidemiology 
Breast cancer represents 14 % of all new cancer cases in the Unites States, 
and approximately 1 in 8 women will develop invasive breast cancer over the course 
of her lifetime [1]. It is the leading diagnosed cancer type representing 29% of all 
cases, and is the second-most-common cause of cancer death in women [2]. Recent 
advances in health care and medical science have accelerated our ability to detect 
the disease in its early stages and have decreased the rate of progression into a 
metastatic state. Nonetheless, the increasing incidence of breast cancer indicates 
the urgent need for developing more advanced treatments and therapeutic 
approaches that can address the molecular mechanisms underlying the disease’s 
aggressiveness, so as to reduce symptom burden and mortality in patients with 
breast cancer. 
1.1.2 Histological classifications of breast cancer 
Breast cancer is a heterogeneous disease classified into different types 
based on the specific cells affected, tumor morphology, aggressiveness, and the 
intrinsic molecular expression [3]. Traditionally, breast cancer is divided into ductal 
carcinomas in situ that originate in the milk ducts, and lobular carcinomas in situ that 
form in the milk gland (Figure 1) [4, 5]. Both ductal and lobular carcinomas can be 
non-invasive, meaning the cancer cells have not spread into surrounding tissue, or 
invasive, meaning the disease cells have disseminated into nearby tissues or distant 
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organs [6]. Invasive ductal carcinoma is the most frequent type (40%–75% of cases 
[4]. 
All breast carcinomas are histologically graded according to the Nottingham 
histological grading system which combines tumor size (T), lymph node invasion (N), 
and spread into distant metastatic sites (M) [7, 8]. In this system, numbers are used 
for each stage to describe the size and location of the tumor (0-3), the degree of 
lymph node invasion (0-3), and presence of distant metastasis (0-1). The breast 
cancer stages are determined by combining TNM classification along with their 
numerical grades, where stage 0 indicates a non-invasive tumor and stages >0 




Figure 1. Histological classification of breast cancer.Figure showing 
categorization of breast cancer based on architectural features and growth patterns. 




1.1.3 Molecular classifications of breast cancer 
Over the past decades, gene expression profiling and next-generation 
sequencing have been used to clarify breast cancer classification and to advance 
predictive prognosis and gnomically-informed therapeutic approaches [9]. In breast 
cancer research, the focus is usually on the molecular profile characteristics, which 
can guide in planning treatment and developing new targeted therapies. 
At the molecular level breast cancers are classified into different subtypes 
based on the expression of hormonal receptors, including estrogen receptor (ER), 
progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) 
(Table 1) [10]. ER and PR, which are expressed in approximately 75% of breast 
cancers, are nuclear receptors that stimulate breast epithelium growth [11]. Luminal 
tumors that start in the luminal lining of the mammary ducts are mostly ER-positive 
and are categorized as luminal A or B. Luminal A tumors are low-grade, ER/PR-
positive, HER2-negative with a low Ki67 score, whereas luminal B tumors are high-
grade, ER-positive, PR-positive/negative, HER2-positive/negative with a high Ki67 
score [12]. Most luminal A tumors are low-grade and are therefore associated with 
better survival rates. The clinical management of these groups includes endocrine 
therapy through ER antagonism (tamoxifen, fulvestrant) and estrogen production 







Table 1.  Molecular classification of breast cancer.Table showing different 
subtypes of breast cancer and their characteristics based on hormonal receptors 
expression. 
The hormone receptor–negative (ER/PR-negative) breast cancers with HER2 
amplification comprise the HER2 subtype. HER2-positive tumors have aggressive 
clinical behavior and poor prognosis, but are responsive to HER-2-targeted 
treatments [15]. On the other hand, approximately 15% of breast tumors are basal-
like triple-negative breast cancers (TNBC) that do not express ER, PR, or HER2 and 
are often associated with an aggressive phenotype with poor clinical outcomes [16, 
17]. 
Another breast cancer subtype is claudin-low tumors, which are triple-
negative (ER/PR/HER2-negative) with an intermediate survival rate that lies 
between those of the basal-like and luminal groups. A hallmark of claudin-low 
tumors is the low expression of luminal and cell adhesion markers including claudin 
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3, 4, and 7 and E-cadherin [18]. Tumors of this subtype are enriched in epithelial-
mesenchymal transition markers and cancer stem cell–like signatures [19]. The 
normal-like breast cancer subtype accounts for 7.8 % of all breast cancer and 
shares a similar immunohistochemical status to luminal A group (ER-positive, PR-
positive/negative, HER2-negative) [20]. The subtype shows a varying gene 
expression profile that includes adipose and stromal genes as well as basal 
epithelial genes [21].  
Comprehensive analysis of breast cancer mutational landscape by using 
next-generation sequencing technologies has provided further information and 
expanded the molecular classification. Such next-generation sequencing studies 
have identified several mutated driver genes in breast cancer including TP53, 
PIK3CA, PTEN, FGFR1, RB1, MYC and GATA3 [22, 23]. The most common 
mutations are PIK3CA, TP53, and GATA3, which have distinct pathological and 
clinical impacts that are differentially expressed across different subtypes [24]. 
PIK3CA mutations are dominant in luminal A and luminal B groups while TP53 
alterations are more prevalent in basal-like breast cancers [11]. The HER2-positive, 
ER/PR-negative breast tumors are associated with mitogen-activated protein kinase 
(MAPK) pathway overactivation and epidermal growth factor receptor (EGFR)/HER2 
signaling signature [25].  
1.2 Current therapies for ER-positive, HER2-negative advanced breast cancer 
1.2.1 Role of ER and estrogen in ER-positive breast cancer 
The ER-positive, HER2-negative luminal breast cancer is the most common 
subtype in women of all racial and ethnic groups and is highly heterogeneous [2]. ER 
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is a transcription factor that regulates the expression of various genes involved in 
cell division and plays an important role in the growth and development of mammary 
glands [26]. ERα and ERβ members of the nuclear receptor family are the two types 
of mammalian ERs that have been identified with ERα being the predominant 
regulator in ER-positive breast cancer, conversely, the role of ERβ is not well known 
[27, 28]. Upon binding of 17β-estradiol (E2) to ER, the receptor is activated and 
binds to specific DNA sequences known as the estrogen response element to drive 
the transcription of target genes [29, 30]. Various transcription factors, coactivators 
and genes regulate the genomic function of ER, such as estrogen receptor 1 
(ESR1), GATA3, and FoxA1 [31, 32]. 
Advanced breast cancer, which includes metastatic and locally advanced 
tumors, has a poor prognosis, with the 5 years survival rate of approximately 26.9% 
[33]. Most metastatic breast cancer is HR-positive (75 %) and HER2-negative (70%) 
[34]. Endocrine therapy is usually the first-line treatment option for these patients 
and includes selective estrogen receptor modulators (SERMs), selective estrogen 
receptor degraders (SERDs), and aromatase inhibitors (AIs) (Figure 2) [35]. 
1.2.2 Selective estrogen receptor modulators    
Similar to estrogen, SERMs act as ligands binding to ER but do not induce 
conformational change or activation of the receptor; thus, they function as agonists 
or antagonists to block the expression of ER-induced genes [36-38]. In randomized 
clinical trials, SERMs were well tolerated with good efficacy and safety [39]. 
Tamoxifen, a nonsteroidal compound, was the first SERM approved by the US Food 
and Drug Administration (FDA) for the treatment of ERα breast cancer [40], and is 
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routinely used to treat all stages of ER-positive breast cancer. Phase III trials of 
tamoxifen have shown a 31% to 69% reduction in breast cancer incidence [41, 42]. 
However, despite its clinical efficacy, long-term exposure to tamoxifen was found to 
increase the risk for developing endometrial cancer [43, 44]. Moreover, expanded 
exposure to SERMs is associated with therapeutic resistance due to multiple 
causes, such as loss of ER expression and acquired ESR1 mutations [45-47]   
1.2.3 Selective estrogen receptor degraders 
In contrast to SERMs, SERDs bind to ERs and function by inhibiting the 
receptor dimerization, thereby inducing its proteasome-dependent degradation and 
ultimately abolishing the ER pathway activity [48]. Fulvestrant is a SERD with an 
antagonist effect that was initially approved as a single-agent, first-line therapy in 
postmenopausal patients with HR-positive advanced breast cancer [49, 50]. 
Preclinical data showed that patients with resistance to tamoxifen respond to 
fulvestrant treatment and that fulvestrant induced growth inhibition in tamoxifen-
resistant tumors [51, 52].    
1.2.4 Aromatase inhibitors  
Aromatase inhibitors (AIs) are anti-estrogenic drugs that block the activity of 
the aromatase enzyme, which converts androgen to estrogen; by doing so, theses 
inhibitors reduce the level of free estrogen that stimulates breast cancer growth [53]. 
The two classes of AIs approved for clinical use include type I steroidals (eg. 
exemestane) and type II nonsteroidals (eg. letrozole) [54]. Genetic polymorphisms in 
the aromatase gene, low-molecular weight cyclin E overexpression, or increased 
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P44/42 MAPK may be responsible for AI therapy resistance in some patients with 
HR-positive, HER2-negative advanced breast cancer [55-57].    
 
       
 
Figure 2.  Mechanism of action of endocrine therapy. The effects of endocrine 
therapies (SERMs, SERDs and aromatase inhibitors) on the estrogen receptor 
pathway. SERMs prevent ER signaling by binding to ER and causing an inactive 
complex, SERDs prevent ER signaling by causing degradation of ER and aromatase 
inhibitors prevent ER signaling by inhibiting synthesis of estradiol (estrogen). 
(Adopted with permission from Patel, H.K. and T. Bihani, Selective estrogen receptor 
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modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer 
treatment. Pharmacology & Therapeutics, 2018). 
1.3 The PI3K/AKT/mTOR pathway in breast cancer 
1.3.1 Biological function of PI3K/AKT/mTOR pathway 
Breast cancer has a high degree of heterogeneity [58], with diverse clinical 
and histological varieties. Understanding the molecular signaling responsible for 
breast tumor heterogeneity is necessary for developing targeted therapeutic 
approaches. Phosphatidylinositol 3-kinases (PI3Ks) are a conserved family of lipid 
kinases divided into three classes based on their structures and specific lipid 
substrates. Class I PI3Ks are heterodimeric molecules that are further divided into 
class IA and class IB. Class IA comprises a p110 catalytic subunit containing three 
isoforms of p110α, p110β and p110δ and a p85 regulatory subunit with five variants 
of p85α, p55α, p50α, p85 β, p55γ. Class IB PI3Ks are heterodimers containing a 
p110γ catalytic subunit and a p101 regulatory subunit [59]. The physiological role of 
class II and III PI3Ks in signal transduction remains unclear.  
In response to extracellular growth signals, receptors tyrosine kinase (RTK) 
binds to PI3K directly or indirectly through insulin receptor substrate (IRS). PI3K 
activation, which can also be induced by G protein-coupled receptor, recruits class I 
PI3K to plasma membrane, relieving p85 inhibition of p110 and resulting in 
phosphorylation of phosphatidylinositol (PtdIns) 4,5-bisphosphate (PIP2) to generate 
PtdIns (3,4,5)-triphosphate (PIP3) [59]. This triggers translocation of AKT, a 
serine/threonine protein kinase B, to the membrane, where it binds to PIP3 through 
its pleckstrin homology (PH) domain, allowing phosphoinositide-dependent kinase 1 
10 
 
to access and phosphorylate AKT at Thr308. Full activation of AKT requires 
phosphorylation of Ser473, which can be catalyzed by PDK2, mechanistic target of 
rapamycin (mTOR) complex 2 (mTORC2), or DNA-dependent protein kinase (Figure 
3).  
Once phosphorylated, activated AKT translocates to various intracellular 
locations where it phosphorylates and modulates the function of numerous 
substrates, many of which are involved in cancer initiation and progression [60]. AKT 
activity is negatively regulated through dephosphorylation by the tumor suppressors 
phosphatase and tensin homolog (PTEN) and pleckstrin homology domain leucine-
rich-protein phosphatase (PHLPP) [61]. PTEN dephosphorylates the PIP3 
component of PI3K back to PIP2, and PHLPP removes the phosphate group from 
AKT at the Ser473 residue [62]. 
Activated AKT phosphorylates a variety of protein substrates involved in 
survival and cellular growth. mTOR, the main downstream target of PI3K/AKT 
signaling, is a key regulator of cell metabolism that once activated phosphorylates 
ribosomal protein S6 kinase (p70S6K) and eIF4E binding-protein-1 (4E-BP1) to 
promote protein synthesis. Tuberous sclerosis complex 1 and 2 (TSC1 and TSC2) 
tumor suppressors which are negative regulators of mTOR/S6K pathway, are 
phosphorylated by AKT, resulting in their inhibition [63, 64]. In addition, AKT 
phosphorylates proline rich AKT substrate of 40 kDa (PRAS40) at Thr246 and yes-
associated protein (YAP) at Ser127 to induce their interactions with 14-3-3 which 
mediates nuclear export [65, 66]. 
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AKT exerts its effect on cell cycle progression by phosphorylating and 
inhibiting cyclin dependent kinase inhibitors p21 and p27, which function as G1 
checkpoints to arrest cell cycle [64]. AKT regulates apoptosis through inhibition of 
BAD, BCL-2-like protein 11, caspase 9, and forkhead box O1 (FoxO1) [67-70]. It 
also phosphorylates mouse double-minute 2 homolog, allowing its entry into the 
nucleus, which results in p53 degradation [71-73] (Figure 3) 
 
 
 Figure 3. Representation of PI3K/AKT/mTOR signaling pathway.   
Shown are the key molecular targets involved in AKT signaling. Upon growth factor 
binding to receptor tyrosine kinase (RTK), phosphoinositol bisphosphate (PIP2) is 
converted to phosphoinositol trisphosphate (PIP3), which recruits AKT and 
phosphoinositide-dependent kinase-1 (PDK1) to the plasma membrane by binding 
the PH domain to membrane lipids. PDK1 and mammalian target of rapamycin 
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complex 2 (mTORC2) phosphorylate AKT, resulting in full activation of AKT. 
Phosphatase and tensin homolog (PTEN) and PH domain leucine-rich-protein 
phosphatase (PHLPP) negatively regulate AKT through dephosphorylation of PIP3 
and AKT (serine-473 residue) respectively. Once activated AKT phosphorylates and 
inhibits the proline-rich AKT substrate of 40 kDa (PRAS40) and tuberous sclerosis 
complex 1 and 2 (TSC1 and TSC2) to promote protein synthesis. AKT blocks 
apoptosis through inhibition of BCL-2-antagonist of cell death (BAD), BCL-2-like 
protein 11 (BIM), and forkhead box protein O1 (FoxO1). It also phosphorylates 
MDM2, resulting in p53 degradation. AKT prevents cell cycle arrest and cyclin D1 
degradation by phosphorylating and inhibiting cyclin dependent kinase inhibitor p27, 
and glycogen synthase kinase 3β (GSK3β). (Adopted with permission from Shariati, 
M. and F. Meric-Bernstam, Targeting AKT for cancer therapy. Expert Opinion on 
Investigational Drugs, 2019. 28(11): p. 977-988.) 
 
Mitogen signals such as insulin-like growth factor 1 (IGF1), activate the 
MAPK/extracellular-signal-regulated kinase (ERK) pathway, resulting in TSC1/TSC2 
complex inhibition, thus stimulating mTOR complex 1 (mTORC1) [74]. In addition, 
the Wnt pathway, a major regulator of cell growth, is involved in mTORC1 activation 
through glycogen synthase kinase (GSK)-3β phosphorylation and subsequent TSC2 
inhibition. The main negative regulator of the pathway is PTEN lipid phosphatase 
which converts PIP3 to PIP2 by removing the 3ʹ phosphate from PIP3. The 
PI3K/AKT pathway negatively controls PTEN at the transcriptional level through 
regulation of transcription factor nuclear factor-κB (NF-κB) and tumor necrosis factor 
α (TNFα), which in turn repress PTEN expression. 
The pathway is also controlled by protein phosphatase 2A and phosphatase 
PHLPP, which dephosphorylate AKT at Thr308 and Ser473, respectively. mTORC1 
triggers the most prominent negative feedback regulation of PI3K signaling. During 
chronic insulin-mediated PI3K stimulation, mTORC1 and S6K activation can lead to 
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downregulation of IRS-1 adopter protein through transcriptional regulation and 
proteasomal degradation [74]. In another negative feedback control mechanism, 
S6K1 is able to phosphorylate IRS-1 at multiple serine residues, preventing its 
binding to RTKs and initiation of PI3K signaling. 
1.3.2 Role of PI3K/AKT/mTOR signaling in carcinogenesis 
The PI3K/AKT/mTOR signaling network is an important pathway that 
integrates extracellular and environmental stimuli translating them into intracellular 
signals that drive cellular functions such as cell growth, proliferation, motility, 
survival, and vesicular trafficking. Aberrant activation of PI3K signaling contributes to 
most cancer hallmarks, including increased cell cycle progression, metabolism, 
survival, and motility. Molecular alterations of the major nodes of this signaling axis 
have been found in numerous tumor types. 
PI3K activity is regulated by growth factor receptors; therefore, any 
modulation in RTKs upstream of PI3K can lead to increases in the pathway activity. 
Mutation activation of EGFR as an activator of PI3K is one of the major alterations in 
the carcinogenesis of non-small cell lung cancer (NSCLC). EGFR gene amplification 
and overexpression is observed frequently in glioblastoma, although it is not very 
common in other cancer types. HER2 is another member of the EGFR family that 
has been overexpressed and amplified in invasive breast and gastric cancer and, 




The PIK3CA gene encoding the p110α catalytic subunit of PI3K is often 
mutated in many human cancer types, including breast, endometrial, colorectal, and 
ovarian tumors. These mutations cluster predominantly in three regions of helical 
(E542K and E545K) and catalytic (H1047R) domains known as “hot spots” (Figure 
4A). The PTEN tumor suppressor gene that antagonizes PI3K signaling is the 
second-most-frequently mutated gene in human cancer. PTEN loss or mutation 
have been identified in both spontaneous and heritable cancers, including 
glioblastoma and endometrial sarcoma. Amplification and activating somatic 
mutation in the PH domain (E17K) of AKT1 (Figure 4B) have been reported in 
breast, colorectal, pancreatic, and ovarian cancers [75].  
 
 
Figure 4. Structural domains of PIK3CA and AKT1 with hotspot mutations. A) 
PIK3CA protein domain. B) AKT1 protein domain. PH: plekstrin-homology domain. 
The most common mutations are listed. The heights of the vertical bars indicate the 
mutation frequency. 
The pathway affects different aspects of tumorigenicity including 
angiogenesis, cell cycle progression, and metastasis. PI3K/AKT/mTOR signaling 
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promotes tumor angiogenesis by shifting the homeostatic balance towards 
proangiogenic factors. Through induction of nitric oxide synthase and inhibition of 
GSK-3β and FOXO proteins, this signaling pathway increases hypoxia-inducible 
factor-1α (HIF-1α) expression, which induces vascular endothelial growth factor 
(VEGF) transcriptional activation [76]. In addition, AKT suppresses endogenous 
angiogenic inhibitor TSP-1 [76]. Thus, the PI3K pathway promotes angiogenesis via 
overexpression of proangiogenic factors, inhibition of antiangiogenic factors, and 
induction of factors that promote the stability of developing vasculature.  
 The PI3K pathway promotes tumor metastasis through several mechanisms. 
It promotes tumor metastasis by activating matrix metalloproteinases and urokinase-
type plasminogen activator, which degrade the extracellular matrix  [76]. In addition, 
the production of chemokines such as C-X-C motif ligand 1 (CXCL-1), 
cyclooxygenase-2 (COX-2), and interleukin-8 (CXCL-8) in conjunction with 
promotion of epithelial-mesenchymal transition by NF-κB and repression of E-
cadherin allows for the cell motility integral to tumor metastasis [76].  
In addition to regulating metastasis, PI3K/AKT/mTOR signaling promotes cell 
cycle progression by increasing transcription of S-phase entry genes and initiation of 
translation of messenger RNAs while inhibiting protein regulators of cell cycle 
progression and pro-apoptotic factors. AKT inhibition of GSK3β and retinoblastoma 
(RB) protein through cyclin-dependent kinase 4/6 (CDK4/6) results in E2F-mediated 
transcription of S-phase entry genes [77]. TORC1-mediated activation of S6K1 and 
inhibition of 4E-BP1, which allows translation of messenger RNAs is required for 
progression to the S phase [77]. In addition, transition to the S phase occurs by 
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inhibiting negative regulators of cell cycle progression such p27 and p21 [77]. 
Finally, inhibition of pro-apoptotic factors such as FOXO3 proteins, mouse double-
minute 2 homolog, and BAD promotes cell cycle progression [77].  
1.3.3 Targeting PI3K and AKT1 in ER-positive breast cancer 
Molecular characterization of differentially expressed genes in breast 
cancer patients over the past decades has shown that novel molecular targeted 
therapies were successful approaches [78, 79]. In the SOLAR-1 clinical trial, 
which randomly assigned patients with HR-positive/HER2-negative advanced 
breast cancer to receive fulvestrant (a selective ER degrader) plus alpelisib (a 
selective PIK3CA inhibitor) or fulvestrant plus placebo, the median progression-
free survival (PFS) was higher in PIK3CA-positive patients receiving alpelisib 
compared with placebo (11.0 months vs. 5.7 months, respectively; HR 0.65 95% 
CI 0.50–1.25 p = 0.00065) [80]. On the basis of this data, the FDA approved 
alpelisib in combination with fulvestrant for postmenopausal women and men with 
HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast 
cancer after progression on an endocrine-based regimen. 
Inhibiting AKT as the central component of frequently disrupted PI3K/AKT 
signaling has long been an attractive therapeutic approach in cancer. Several 
compounds for targeting AKT are in clinical development. The two classes of AKT 
inhibitors include adenosine triphosphate (ATP)-competitive and allosteric inhibitors. 
The ATP-competitive inhibitors bind to the active site of AKT, blocking ATP binding, 
whereas allosteric inhibitors bind to the PH domain, preventing AKT phosphorylation 
and activation [81]. Although the three AKT isoforms have structural similarity, there 
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are differences in their functions, tissue distribution, and substrate specificity [82]; 
thus, the impact of novel therapeutics on different isoforms in vivo needs further 
study. 
Recently, AKT inhibitors have shown preliminary signal of activity in HR-
positive breast cancer with AKT mutations [83]. However, as the PI3K pathway is 
involved in the survival and proliferation of normal cells, the therapeutic-index of 
these strategies is quite narrow. For example in the SOLAR-1 trial, adverse 
events (grade ≥3) occurred in 64.4% of patients receiving alpelisib and fulvestrant 
compared with 30.3% of those receiving placebo and fulvestrant [80]. Thus, the 
toxicity profile of PI3K/AKT pathway-targeted therapies has limited enthusiasm 
towards their clinical use. Hence, there remains a need for novel therapies 
targeting vulnerabilities in PIK3CA or AKT1 mutant breast cancer. 
1.4 Cell cycle in breast cancer 
1.4.1 Cell cycle process 
An uncontrolled cell cycle as a critical regulator of growth and proliferation is 
one of the hallmarks of cancer [84]. The cell cycle is composed of four ordered 
phases: G1 (Gap 1) phase, S phase (DNA synthesis), G2 (Gap 2) phase, and M 
(Mitosis) phase. The progression through these phases is tightly regulated by a 
group of proteins called cell cycle checkpoints, comprising cyclins and cyclin-
dependent kinases (CDKs), that monitor the integrity of DNA replication and prevent 
genomic instability which can consequently drive tumorigenesis [85, 86]. In the 
presence of DNA damage, checkpoints induce cell cycle arrest through CDK 
inhibitions to repair the error or trigger cell death or senescence (Figure 5) [87]. 
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1.4.2 The regulation of cell cycle in breast cancer 
In preclinical studies, cyclin D1-dependent CDK4/6 kinases activity is required 
to form luminal breast cancer and maintain tumorigenesis [88, 89]. Aberrant 
activation of mitogenic signaling, including PI3K/AKT/mTOR, MAPK/ERK, and ER 
transcriptional activity (in the case of ER-positive breast cancer), increase CCND1 
expression level and/or cyclin D1 protein stability, resulting in the formation of cyclin 
D1-CDK4/6 complex, which mediates cell cycle progression from G1 phase to S 
phase (Figure 6) [90-92]. Cyclin D1-dependent CDK4/6 activation leads to the 
phosphorylation and inactivation of RB which liberates E2F transcription factors and 
further drives the expression of genes that promote G1 to S phase transition 





Figure 5. Function of CDK4/6 in cell cycle progression. Active complex of 
CDK4/6 and cyclin D phosphorylates and inactivates RB protein and then releases 
transcription factor E2F, triggering the up-regulation of E2F-responsive gene which 
promotes cell proliferation with cell cycle G1/S transition.  
 
1.4.3 Role of CDK 4/6 inhibitors in breast cancer 
Given the critical role of CDK4/6 in breast cancer formation, several selective 
inhibitors with distinct potencies have been developed. The overexpression of cyclin 
D1 frequently occurs in HR-positive breast cancer, while loss of RB is uncommon. 
CDK4/6 facilitate G1 to S phase transition during cell cycle progression, which 
makes them ideal therapeutic targets in breast tumors with functional RB [94]. 
Preclinical and clinical antitumor activity in response to CDK4/6 inhibitors has been 
observed in ER-positive breast cancer [95, 96]. The data support significant 
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improvement in PFS and synergistic activity when CDK4/6 inhibitors are combined 
with endocrine therapy, resulting in the approval of CDK4/6 inhibitors for the 
treatment of ER-positive, HER2-negative advanced metastatic breast cancer (Figure 
6) [97]. 
1.5 Approved CDK 4/6 inhibitors for ER-positive, HER2-negative breast 
cancer treatment 
1.5.1 Palbociclib  
Palbociclib (PD-0332991) was the first CDK4/6 inhibitor with highly selective 
enzymatic activity for both CDK4 and CDK6 that showed anti-tumor activity against 
breast cancer cells [95, 98]. It also exhibited synergy when used with endocrine 
therapy in ER-positive cell lines. In the PALOMA-1/TRIO-18 phase II clinical trial, the 
addition of palbociclib to letrozole (an aromatase inhibitor) significantly improved 
PFS, compared with letrozole alone (20.2 vs 10.2 months; hazard ratio [HR], 0.488; 
95% CI, 0.319–0.748; P=0.0004) [95, 99]. This led to the approval of palbociclib plus 
letrozole as the first-line treatment of postmenopausal women with ER-positive, 
HER2-negative advanced breast cancer [100]. In the PALOMA-3 randomized phase 
III clinical trial, 521 postmenopausal women with HR-positive, HER2-negative 
advanced breast cancer whose cancer had progressed during previous endocrine 
therapy randomly received palbociclib plus fulvestrant or placebo plus fulvestrant. 
The median PFS was higher in patients in the palbociclib plus fulvestrant group than 
the placebo plus fulvestrant group (9.5 vs 4.6 months; HR, 0.46; 95% CI, 0.36–
0.59; P < .0001) [97, 101]. Based on these data, the FDA approved palbociclib in 
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combination with fulvestrant for the treatment of HR-positive, HER2-negative 
advanced or metastatic breast cancer as a second-line treatment [97, 102].      
1.5.2 Ribociclib  
Ribociclib (LEE011) is a highly selective CDK4/6 inhibitor with in vitro half 
maximal inhibitory concentrations (IC50s) of 10 nM and 40 nM for CDK4 and CDK6, 
respectively [103]. In the MONALEESA-2, a phase III randomized clinical trial, 668 
previously untreated postmenopausal women with HR-positive, HER2-negative 
advanced breast cancer received ribociclib plus letrozole or placebo plus letrozole. 
Final analysis showed an improved PFS in the ribociclib plus letrozole group 
compared with the placebo plus letrozole group (25.3 vs 16 months; HR, 0.56; 
p<0.001) [104, 105]. On the basis of these data, the FDA approved ribociclib in 
combination with letrozole for the first-line treatment of postmenopausal women with 
HR-positive, HER2-negative advanced or metastatic breast cancer [106]. In addition, 
in the MONALEESA-3 phase III clinical trial, postmenopausal women with HR-
positive, HER2-negative advanced breast cancer received ribociclib or placebo plus 
fulvestrant. The addition of ribociclib improved PFS from 12.8 months to 20.5 
months (HR, 0.593; p<0.001) which also led to the approval of ribociclib in 
combination with fulvestrant in this group as first-line or second-line treatment [107]. 
1.5.3 Abemaciclib  
Abemaciclib (LY2835219) is also a highly selective CDK4/6 inhibitor that has 
been shown to inhibit other kinases, including CDK9 and PIM1 [108, 109]. It induced 
cell cycle arrest in the G1 phase and inhibited the proliferation of breast cancer cell 
lines [108]. In the MONARCH-2 phase III clinical trial, 669 patients with HR-positive, 
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HER2-negative advanced breast cancer who had previous endocrine therapy were 
randomly treated with fulvestrant  plus either abemaciclib or placebo. Median PFS in 
the abemaciclib-treated arm improved significantly, compared with the placebo-
treated arm (16.4 vs 9.3 months; HR, 0.553; 95% CI, 0.449–0.681; P < 0.001) [110]. 
In the MONARCH-3 phase III trial, 493 previously untreated patients with HR-
positive, HER2-negative advanced breast cancer received abemaciclib plus letrozole 
or placebo plus letrozole. The abemaciclib group had a longer median PFS (28.18 
months) than the placebo group (14.76 months) [111]. Abemaciclib was approved to 
be used with fulvestrant for the second-line of therapy in women with HR-positive, 
HER2-negative advanced breast cancer on the basis of the results of the 
MONARCH-2 trial and was later approved as first-line therapy in combination with 
an aromatase inhibitor for postmenopausal women on the basis of the MONARCH-3 









Figure 6. CDK4/6 inhibitors and the upstream mitogenic forces inducing cyclin 
D1 and activating CDK4/6.Upstream mitogenic signaling pathways, including ER 
transcriptional activation and, PI3K/AKT/mTOR, and MAP/ERK pathways activation 
increase CCND1 expression level and/or cyclin D1 protein stability resulting in the 
formation of cyclin D1-CDK4/6 complex which mediates cell cycle progression from 
G1 to S phase. Palbociclib, ribociclib and abemaciclib are pharmacologic CDK4/6 
inhibitors that directly inhibit the CDK4/6 activity.  
 
 
1.5.4 Mechanism of resistance to CDK 4/6 inhibitors in breast cancer 
The development and approval of CDK4/6 inhibitors over the past 2 
decades has been a major therapeutic milestone for the treatment of ER-positive, 
HER2-negative metastatic breast cancer. Multiple studies have shown that ER-
positive cell lines with luminal features were most sensitive to palbociclib—the 
highly selective inhibitor of CDK4/6—[95, 113] but that efficacy was limited by 
acquired resistance. Mechanisms driving resistance to CDK 4/6 inhibitors have 
not been clearly defined. Recently, whole-exome sequencing of 59 metastatic 
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tumors treated with CDK4/6 inhibitors revealed multiple potential resistance 
mediators, including RB1 loss, that activate alterations in AKT1, AURKA, CCNE2, 
RAS, FGFR2, and ERBB2 [114].  
Alterations of the PI3K/AKT pathway are crucial to developing resistance to 
endocrine therapy [115]. Recently, activation of this pathway has been reported to 
correlate with resistance to CDK4/6 inhibitors [116, 117]. PI3K pathway-dependent 
activation of non-canonical cyclin D1/CDK2 and the resultant recovery of RB 
phosphorylation and S- phase entry has been shown to drive resistance to CDK4/6 
inhibition [118]. Consequently, the role of PIK3CA and AKT1 inhibitors in overcoming 
resistance has been investigated in both pre-clinical and clinical studies. Although 
combining endocrine therapy with CDK4/6 and PIK3CA inhibitors may help prevent 
acquired CDK4/6 resistance in a preclinical setting, this approach may produce 
considerable toxicity in the clinic [119-121].  
1.6 Goal of the study 
Although recent medical advances in breast cancer treatment have been 
promising, lack of effective targeted treatments addressing tumor heterogeneity 
necessitates an improved therapeutic strategy that is based on the genetic profiles 
of the patients. The PI3K oncogenic pathway is frequently enhanced in ER-positive, 
HER2-negative breast tumors. This has prompted a sizeable effort toward 
developing agents that target this pathway at various points. Preclinical studies 
suggest that the activity of such agents will be enhanced in tumors with PIK3CA or 
AKT1 mutations [122, 123]; however, the efficacy of these compounds is not limited 
to specific genetic alterations. In clinical trials, PI3K pathway inhibitors have limited 
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therapeutic efficacy as single agents, and the presence of PIK3CA mutations do not 
guarantee a dramatic response. Further, neither the Phase III trial of the mTOR 
inhibitor everolimus plus exemestane (BOLERO 2), nor the Phase II trial of the PI3K 
inhibitor pictilisib plus fulvestrant (FERGI) in HR-positive breast cancer [124], found 
differential benefit in patients with PIK3CA mutant tumors [125].  
CDK4/6 inhibitors have revolutionized ER-positive, HER2-negative metastatic 
breast cancer treatment and have become the standard of care in combination with 
endocrine therapy. However, their efficacies are restricted by intrinsic or acquired 
resistance. As there is a profound cross-talk between CDK4/6 and the PI3K pathway 
in the survival and proliferation of normal cells, a therapeutic index making 
PIK3CA/AKT1 mutant tumors more sensitive to palbociclib than normal tissues may 
be an efficacious approach. To overcome clinical resistance to CDK4/6 inhibitors, it 
will be necessary to find additional targets by identifying other potential survival 
pathways that take advantage of PIK3CA and AKT1 driving mutations to promote 
ER-positive tumor growth.   
The goal of this study was to enhance the antitumor efficacy of 
palbociclib in ER-positive, HER2-negative breast cancer with PIK3CA or AKT1 
mutations with combinational agents that target alternative adaptive survival 
signaling. This was addressed by using a human kinome shRNA library and next-
generation sequencing to identify synthetic lethal interactors for palbociclib in the 
context of ER-positive breast cancer having PIK3CA or AKT1 mutations. Further, 
the study aimed to investigates the effects of PIK3CA and AKT1 mutations on 



















CHAPTER 2:  MATERIALS AND METHODS 




2.1 Cell lines  
The isogenic MCF7 ER-positive breast cancer cell line and its derivatives 
were established through somatic gene targeting technique as previously described 
[126]. These cell lines were parental MCF7 with one wild-type and 2 E545K alleles 
(MCF7-PIK3CA), wild type MCF7 with three copies of wild type PIK3CA (MCF7-WT), 
and wild type MCF7-WT with knock in AKT1-E17K constitutively active mutation 
(MCF7-AKT1). Authentication of the MCF-7 cell lines was verified using DNA 
fingerprinting technique based on National Cancer Institute (NCI) public database at 
MD Anderson Cancer center Core Facility. In addition, droplet digital polymerase 
chain reaction (PCR) procedure was performed to confirm the status of PIK3CA and 
AKT1 mutations in the MCF7 isogenic cell lines. 
2.2 Cell culture conditions 
All cells were maintained in Dulbecco's Modified Eagle Medium (DMEM)/F12 
media with L-glutamine (Corning cellgro) supplemented with 10% FBS (fetal bovine 
Serum, Sigma). The cell culture was carried out at 37° C in a humidified incubator 
with 5% CO2. The non-transformed immortalized human breast epithelial cell lines, 
MCF-10A, were maintained on the same standard cell culture condition described. 
The cells grew in complete MCF-10A growth medium containing mammary epithelial 
cell basal medium (MEBM) (Lonza Walkersville, Inc.) supplemented with 5% horse 
serum (Invitrogen), 20 ng/ml human epidermal growth factor (hEGF), 10 μg/ml 
insulin, 0.5 μg/ml hydrocortisone, 100 ng/ml cholera toxin, and 100 μg/ml 
streptomycin. Trypsin-ethylenediaminetetraacetic acid (EDTA) (0.25%) solution 
(Gibco, Invitrogen) was used for the dissociation and subculturing of the cell lines. 
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2.3 Drug cytotoxicity and proliferation assay 
The pharmacologic drugs palbociclib (LC Laboratories) and 7rh benzamide 
(Carbosynth) used for cytotoxicity assay. Cells were seeded at a density of 3 x 103 
cells per well in 96-well plates to adhere overnight. The next day they were treated 
with five different concentrations of each drug and dimethyl sulfoxide (DMSO) in a 5-
fold serial dilution series. Each condition was in triplicate. After 72 hours the cells 
were fixed with 50 µl of 5% trichloroacetic acid (TCA) per well for 1 hour at 4° C. 
After fixing and drying 100 µl 0.4% sulforhodamine B (SRB) solution was added to 
each well and the plates were incubated at room temperature for 1 hour. The wells 
were washed with 1% acetic acid to remove unbound SRB dye. 100 µl of 10 mM Tris 
base solution (pH 10) was added to each well to solubilize the protein-bound dye. 
The optical density (OD) value was measured at 510 nm in Synergy 4 
microplate reader (Bio Tek). The data were analyzed to determine the half maximal 
inhibitory concentration (IC50) and combination index (CI) based on the Median 
Effect methods using the dose-effect analyzer software CalcuSyn 2.0. To measure 
proliferation rate, cells were seeded in triplicate at a density of 2 x 103 cells per well 
in several 12-well plates. Cells were harvested every two days and diluted 1:1 with 
Trypan Blue solution to count the viable cells using Countess II automated cell 
counter (Life Technologies). Experiment was repeated three times. 
2.4 Clonogenic survival assay 
Cells were seeded at 1 x 103 cells per 60 mm plate in triplicate and treated 
with different doses of palbociclib and 7rh for 3 weeks until the control approached 
confluency. Fresh medium containing the drug was added to the wells twice a week. 
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Plates containing the colonies were then washed twice with phosphate-buffered 
saline (PBS) and fixed in 10% formalin for 15 minutes at room temperature. After 
fixation process, the cells were stained in 0.05% crystal violet with 25% methanol for 
10 minutes. After the removal of crystal violet, the plates were washed several times 
with water before image acquisition using a scanner. NIH ImageJ v.1.46 software 
was used to count the colonies.  
2.5 FACS analysis of cell cycle  
Cells were seeded at 5 x 105 cells per 100 mm plate in triplicate and treated 
with various doses of palbociclib and 7rh. After 48 hours, the cells were collected 
and fixed in cold 70% ethanol, then washed twice with PBS. To remove double-
stranded RNA, 1 U of RNase, DNase free was added to the cell suspensions and 
incubated at 37° C for 1 hour. The cells were stained with propidium iodide (Roche), 
stored at +2° C to +8° C, and protected from light until flow cytometric analysis. 
Percentages of cells in different phases of the cell cycle were determined using a 
Gallios flow cytometer (Beckman Coulter Inc.) and analyzed with Kaluza analysis 
software (Beckman Coulter Inc.). 
2.6 Soft agar assay 
MCF-10A cells were seeded at 1 x 105 cells per well of six-well plates. The 
wells were coated with 0.5% agarose/1X medium composed of low-melting agar 
(Difco Agar Noble, BD), DMEM powder (Sigma), and FBS (base agar) and overlaid 
with 2 ml 0.35 % agarose/1X medium solution containing the cells (top agar). The 
soft-agar cultures were maintained at 37° C in a humidified incubator with 5% CO2, 
and the top agar medium was replaced with fresh medium every other day. Colonies 
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were then fixed with 0.05% iodonitrotetrazolium chloride (INT) prepared at 0.5 mg/ml 
in PBS and incubated overnight at 37° C. Images for both bright field and red 
fluorescent protein (RFP) were obtained by using FluorChem 8900 (Alpha Innotech). 
2.7 Immunoblotting 
The primary antibodies used are listed in Table 2. Whole cell protein extracts 
prepared with Laemmli buffer, were heated in sample buffer for 5 min at 95° C. 
Approximately 30 µg of each sample loaded in 10% SDS-PAGE and transferred to 
nitrocellulose membranes (Bio-Rad). After blocking in bovine serum albumin (BSA) 
for 1 hour, the membranes were probed with the indicated antibodies diluted in Tris-
buffered saline with 0.1% Tween 20 (TBST) with 5% BSA (Sigma) and incubated 
overnight at 4° C. The membranes were then washed 3X in TBST and incubated 
with secondary antibody for 1 hour at room temperature. Detection was performed 









           Table 2. List of primary antibodies. 
 
 
2.8 shRNA library screening 
The human kinome (hkinom) shRNA library in pRSI vector tagged with GFP 
cDNA and expressing puromycin resistance gene, was provided by the Center for 
Co-Clinical Trials (CCCT) at the University of Texas MD Anderson Cancer Center 
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(Human DECIPHER, Cellecta Inc.). Prior to transduction the optimal concentrations 
of polybrene and puromycin were calculated based on toxicity kill curve experiment. 
Polybrene toxicity titration in target cells was performed by growing cells in culture 
medium with a range of polybrene concentrations (0 μg/ml, 1 μg/ml, 2 μg/ml, 4 
μg/ml, 6 μg/ml, 8 μg/ml) for 24 hours then replaced with polybrene-free culture 
medium. Cells grew for an additional 72 hours and toxicity was checked by counting 
viable cells. The highest concentration of polybrene that results in less than 10% cell 
toxicity compared to no polybrene was selected for shRNA library transduction. 
Puromycin kill cure was generated by treating the target cells with a range of 
puromycin concentrations (0 μg/ml, 0.5 μg/ml, 1 μg/ml, 2 μg/ml, 5 μg/ml, 10 μg/ml). 
The cells grew under standard conditions and the lowest concentration that kills 
>95% of cells in 48 hours was selected for screening. 
Before the lentiviral library transduction, a range of MOI (0, 0.15, 0.3, 0.5, 1, 
and 2) was used to determine the desired one for 20% transduction. The number of 
viral particles required to achieve different MOI was calculated as below using the 
stock virus titer of 2.05 x 108 TU/ml: 
a. Number of cells seeded x desired MOI = # of TU required 
b. # of TU / Functional titer of pRSI virus = amount of virus to add to each 
well. 
c. TU/ml = (# of cells at Transduction) x MOI / (ml of Viral Stock used at 
Transduction) 
For reverse transduction, 1 x 105 cells for approximately 95% confluency in 72 
hours added in each well of 6-well plate in media containing 8 μg/ml polybrene and 
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transduced by adding the calculated amount of viral particle to each plate. The next 
day viral media was replaced with normal growth media (no polybrene). After an 
additional 48 hours, the % of infected cells was determined by observing the % of 
GFP positive cells in each transduced cell sample using flow cytometry. The MOI 
and viral integration was calculated based on Poisson distribution and the MOI 
required (in the range of 0.2-1.5) for 20% transduction efficiency was determined for 
the eventual complexity test drop-out screen. 
 
                      
Figure 7. MOI and viral integration calculated based on Poisson 
distribution.Cells were transduce in suspension by adding the calculated number of 
viral particles (described above) equivalent to a range of MOI (0 to 1). 48-72 hours 
post transduction, the % of infected cells was determined by flow cytometry by 
observing the % of GFP+ cells. 
 
  
Using the calculated MOI (Figure 7), viral transduction was performed as 
before and the transduced cells cultured in media containing 2 μg/ml puromycin for 
















Titer chart of pRSI 
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(stored at -80° C) at the beginning of the two weeks treatment period to eventually 
compare the shRNA barcode abundance to the drug treated cells.  
2.9 shRNA gene silencing and plasmid overexpression 
For silencing, pLKO-puro lentiviral vectors containing DDR1 and control 
shRNA constructs were obtained from shRNA Mission (Sigma-Aldrich). To generate 
viral particles, 293T cells were transfected with shDDR1 and non-targeting control 
shRNA along with psPAX2 (packaging) and pCMV-VSV-G (envelope) expression 
constructs using Lipofectamine 2000 transfection reagent (Invitrogen). 
The viral supernatants were harvested at 24 and 48 hours post transfection, 
centrifuged at 500 g for 5 minutes to pellet any packaging cells and filtered through 
0.45 μm PES filter. Prior to transduction the optimal dose of antibiotic selective 
marker was obtained by treating target cells with a range of puromycin 
concentrations (0 μg/ml, 0.5 μg/ml, 1 μg/ml, 2 μg/ml, 5 μg/ml, 10 μg/ml) for 48 hours 
and toxicity was checked by counting viable cells to determine the lowest dose that 
kill more than 95% of the cells. The day before transduction, 1 x 105 cells seeded in 
each well of 6-well plates to exhibit 30-40 % confluency at the time of transduction. 
The lentiviral particles supplemented with 8 µg/ml polybrene added to the cells and 
incubated overnight. One days after infection cells treated with medium containing 2 
µg/ml puromycin for 2 more weeks. 
For selection of stable cells, puromycin added to the cell culture medium and 
replaced every 3 days until resistant colonies identified. The antibiotic resistant pools 
were examined for DDR1 protein expression by western blot and frozen at each cell 
passage. DDR1 wild type expression vector, pHAGE-puro-DDR1, was generated by 
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Gateway LR reaction from pDNOR-DDR1 to pHAGE-puro vector. DDR1 mutants 
expression vectors were generated by PCR-based mutagenesis as described before 
[127], and cloned into pHAGE-puro vector by Gateway LR reaction. 
2.10  Quantitative real-time PCR 
Total cellular RNA was extracted (Qiagen RNeasy Mini Kit) and 1 µg was 
used for cDNA synthesis using SuperScript III First-Strand Synthesis kit (Invitrogen) 
according to manufacturer’s protocol. Quantitative real-time (qRT)-PCR reaction was 
performed in SYBR GreenER qPCR SuperMix cocktail (Invitrogen) using the primers 
for the gene of interest [128] (obtained from PrimerBank at The center for 
Computational and Integrative Biology, Harvard Medical School). The mRNA levels 
were measured with 7500 Real-Time PCR System (Applied Biosystems). Each qRT-
PCR experiment was repeated three times in technical triplicate and mRNA levels 
were normalized to GAPDH expression applying ΔΔCt relative quantification 
method. The following primers were used for qRT-PCR: 
PrimerBank ID: 378404907c2 
GAPDH-Forward: 5’ ACAACTTTGGTATCGTGGAAGG 3’  
GAPDH-Reverse: 5’ GCCATCACGCCACAGTTTC 3’  
 
PrimerBank ID: 321400062c2 
DDR1-Forward: 5’ CCGACTGGTTCGCTTCTACC 3’  
DDR1-Reverse: 5’ CGGTGTAAGACAGGAGTCCATC 3’ 
 
PrimerBank ID: 340545541c3 
FoxM1-Forward: 5’ ATACGTGGATTGAGGACCACT 3’  




PrimerBank ID: 34147632c3  
PLK1-Forward: 5’ CCTGCACCGAAACCGAGTTAT 3’  
PLK1-Reverse: 5’ CCGTCATATTCGACTTTGGTTGC 3’ 
PrimerBank ID: 310832423c1  
CDKN1A (P21)-Forward: 5’ TGTCCGTCAGAACCCATGC 3’  
CDKN1A (P21)-Reverse: 5’ AAAGTCGAAGTTCCATCGCTC 3’ 
Real-time instrument was programmed as shown below:  
• 50° C for 2 minutes   
• 95° C for 10 minutes  
40 cycles of:  
• 95° C for 15 seconds 
• 60° C for 60 seconds 
 
2.11 Reverse phase protein array (RPPA) analysis 
The RPPA was performed in the MD Anderson Cancer Center RPPA core 
facility. To prepare samples for RPPA, the xenograft tumor tissues were dissected 
on dry ice and lysed in lysis buffer containing 1% Triton X‐100, 50mM HEPES, pH 
7.4, 150mM NaCl, 1.5mM MgCl2, 1mM EGTA, 100mM NaF, 10mM Na 
pyrophosphate, 1mM Na3VO4, 10% glycerol, protease and phosphatase inhibitors 
(Roche). The protein concentration was determined by BCA assay (Pierce) and 
adjusted to 1.5 µg/µl for all the samples using lysis buffer for dilution. The cell lysate 
were mixed with 4X SDS sample buffer containing 40% Glycerol, 8% SDS, 0.25M 
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Tris‐HCL pH 6.8, and 0.1 % beta‐mercaptoethanol (B‐Me) at the ratio of 1 to 4 then 
boiled for 5 minutes at 100° C and stored at −80° C. 
The lysates were printed on nitrocellulose-coated slides using Aushon 
Biosystems 2470 arrayer and probed with a total of 400 primary antibodies followed 
by the appropriate biotinylated secondary antibodies for detection. The slides were 
scanned with Array-Pro Analyzer software for generation of spot intensity. 
SuperCurve GUI [129] was used to estimate relative protein level in log2 scale. 
RPPA slides quality was determined with a QC metric [130] and only the slides with 
0.8 on a 0-1 scale were included for further processing. Protein measurements were 
corrected using median-centering across antibodies and samples with low protein 
level were excluded for further analysis. The data were normalized and centered to 
present the protein mean expression value in Log2.  
2.12 In vivo experiments 
All animal experiments were approved by the University of Texas MD 
Anderson Cancer Center Institutional Review Board and in accordance with the 
Institutional Animal Care and Use Committee (IACUC) guidelines. MCF7-PIK3CA 
cells (10x106) were re-suspended in 200 µl of 1:1 matrigel (Corning Life Sciences) in 
DMEM medium without serum and injected into mammary fat pads of 6 weeks old 
female NSG (NOD scid gamma) mice (The Jackson Laboratory) supplemented with 
17β-estradiol pellets. The treatment started when tumor mean volumes reached 
approximately 200 mm3 and the animals were randomly assigned to four treatment 
groups (5 mice in each group). Drugs were dissolved in 1% carboxymethyl cellulose, 
0.25% Tween 80. Animals were treated daily with oral administration of palbociclib 
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(25 mg/kg) once a day and 7rh (25 mg/kg) twice a day. The tumor sizes were 
measured with a caliper every 4 days and the volumes were calculated using V 
(mm3) = ab2/2 equation, where “a” is the largest diameter and “b” is the smallest 
diameter. At the end of the experiment, mice were euthanized 4 hours after the last 
treatment and the tumors were extracted for further analysis in IHC and RPPA. 
Compressed CO2 gas in cylinders was used for the euthanasia chamber at the flow 
rate of 20% of the chamber volume per minute.     
2.13 Immunohistochemical staining of human xenografts 
The harvested xenograft tumor tissues were fixed in 10% Neutral Buffered 
Formalin (NBF) for 24 hours at room temperature and embedded in paraffin (Sigma). 
The FFPE tissues were cut into 4µm, mounted on Plus glass slides and evaluated 
for hematoxylin and eosin (H&E) staining. 
The paraffin-embedded sections were deparapffinized in xylene and hydrated 
in graded alcohols (100%, 95% ETOH). The endogenous peroxidase activity was 
blocked with 3% H2O2 in water. Antigen retrieval was performed in 10 mM Citrate 
Buffer (pH 6.0) in microwave for 15 minutes under standardized conditions then 
cooled down for 20 minutes and washed with water. Non-specific antibody binding 
was blocked by incubating slides with Biocare Blocking Reagent # BS966M (Casein 
in buffer) for 10 minutes. Immunostaining was done by incubating the slides for 15 
minutes at room temperature (Ki67) or overnight at 4° C (phospho-Rb and P21) 
using the primary antibodies against Ki67 (clone MIB-1, mouse monoclonal from 
DAKO cat. # M7240, at 1:100 dilution), phospho-Rb (Ser-780) (EPR182N, rabbit 
monoclonal from Abcam cat. # ab173289, at 1:100 dilution), P21 (F-5, mouse 
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monoclonal from Santa Cruz # sc-6246, at 1:50 dilution) with negative and positive 
controls for each experiment. 
 The slides were incubated with Envision plus labeled polymer, anti-rabbit-
HRP (Dako) for 30 minutes at room temperature and visualized using Dako DAB 
monitoring staining development kit (Sigma). The tissue processing and 
immunohistochemical staining were carried out at the MD Anderson Cancer Center 
Research Histology Core Laboratory (RHCL) and Research Histology, Pathology 
and Imaging Core (RHPI).  
2.14 Immunohistochemical scoring and imaging  
The immunohistochemical staining was evaluated by a pathologist under 
Olympus BX46 microscope. For Ki-67 and phospho-Rb the percentage of positive 
cells in the tumor was estimated.  For P21 and Bcl-2 the percentage of positivity (0% 
to 100%) and the staining intensity (0 = no staining, 1+ = weak staining, 2+ = 
moderate staining, and 3+ = strong staining) were evaluated resulting in an H-score 
by multiplying percentage and intensity (range: 0-300). Images were obtained by 
scanning the slides at 40X using Olympus DP27 Microscope Digital Camera. 
2.15  Statistical analysis 
Comparison between two groups was done using two-way student t test with 
GraphPad Prism software. All the in vitro experiments were performed three times 
and the data were presented as mean ± SE (SEM). The p value that was used as a 
cutoff for determining significance was 0.05 (p value < 0.05). For RPPA data 
analysis, differentially expressed proteins (DEPs) between treatment groups were 
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identified by fitting linear model and making contrast with R package Limma. False 
discovery rate (FDR) of 0.05 was used as the cutoff value. For in vivo data, two-way 
ANOVA and Tukey’s multiple comparison test were applied to analyze the 
significance of tumor volume in different treatment groups. P-value calculated based 
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3.1 INTRODUCTION 
Molecular alterations in the PI3K/AKT pathway occur in more than 30% of ER- 
positive invasive breast tumors [131]. These genetic mutations include genes 
encoding the PI3K catalytic subunits p110α (PIK3CA) and the PI3K effector AKT1. 
Aberrant PI3K/AKT signaling is implicated in the pathogenesis of ER-positive breast 
cancers [132] and therefore is a major focus of drug development. 
Despite the efficacy of the available small-molecule inhibitors for targeting 
different components of PI3K pathway, the contribution of PIK3CA and AKT1 genetic 
alterations to targeted therapy is not well understood. Even though PI3K 
pathway mutations occur at a high frequency in breast cancer, little work has been 
done to elucidate the biological and clinical significance of PIK3CA and AKT1 
alterations. To address functional consequences of PIK3CA and AKT1, we 
examined the differential effects of these “hot spot” mutations on proliferation and 
tumor growth.    
CDK4/6 plays a key role in the proliferation of breast cancer as well as the 
development of normal breast tissue, which establishes a strong rationale for 
targeting these kinases. CDK4/6 inhibitors have profoundly impacted ER-positive, 
HER2-negative metastatic breast cancer treatment and have become the standard 
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of care in combination with endocrine therapy. However, their efficacy is restricted 
by intrinsic or acquired resistance. Both preclinical and clinical data support the 
activation of upstream PI3K mitogenic pathway as a potential mechanism of 
resistance [118, 133]. Thus, we determined the effect of PIK3CA and AKT1 
mutations on palbociclib sensitivity, which will ultimately help to identify predictive 
biomarkers and optimal targeted therapies in combination with CDK4/6 inhibitors. 
The use of isogenic cell lines is a complementary approach to study the influence 
of genotype on drug sensitivity. This will eliminate the effect of other alterations that 
could impact treatment efficacy and provide a model system with a uniform 
phenotypic effects. To date, none of the identified human breast cancer cell lines 
has an AKT1 mutation and thus the use of AKT1 knock-in model helps us to better 
assess the effect of this mutation.    
3.2 RESULTS 
3.2.1 Validation and authentication of MCF7 isogenic cell lines  
The isogenic MCF7 ER-positive breast cancer cell line and its derivatives 
were established by using a somatic gene–targeting technique, as previously 
described [126]. These cell lines were parental MCF7 with one wild-type and two 
E545K alleles (MCF7-PIK3CA), wild-type MCF7 with three copies of wild-type 
PIK3CA (MCF7-WT), and wild-type MCF7-WT with knock-in AKT1-E17K 
constitutively active mutation (MCF7-AKT1). Authentication of the MCF-7 cell lines 
was verified by using a DNA fingerprinting technique based on a National Cancer 
Institute (NCI) public database (Table 3). In addition, droplet digital PCR procedure 
was performed to confirm the status of PIK3CA and AKT1 mutations in the MCF7 
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isogenic cell lines. The droplet digital PCR revealed that all mutants were expressed 




Table 3.  DNA fingerprinting of the isogenic MCF7 cell lines. DNA fingerprinting 
using the CCSG databases verified the authentication of the MCF7 cell lines. CCSG 
database is a comprehensive databases of short tandem repeat (STR) profiles. The 
database includes profiles from 20 public database/ publications and the cell lines 
developed by MD Anderson research labs. The database contains over 2500 unique 
human cancer cell line STR profiles, one of the largest cancer cell line STR online 










Sample name: MCF7 MCF7-WT MCF7-PIK3CA MCF7-AKT1
AMEL X X X X
CSF1PO 10 10 10 10
D13S317 11 11 11 11
D16S539 11,12 11,12,13 11,12 11,12,13
D18S51 14 14 14 14
D21S11 30 30 30 30
D3S1358 16 16 16 16
D5S818 11,12 11,12 11,12 11,12
D7S820 8,9 8,9 8,9 8,9
D8S1179 10,14 10,14 10,14 10,14
FGA 23,25 23,25 23,25 23,25
TH01 6 6 6 6
TPOX 9,12 9,12 9,12 9,12
vWA 14,15 14,15 14,15 14,15




















Figure 8. Validation of PIK3CA and AKT1 alterations in MCF7 isogenic cell 
lines.Droplet digital PCR was performed using the genomic DNA isolated from the 




3.2.2 Growth characterizations and effects of PIK3CA and AKT1 mutations in 
vitro and in vivo 
First, we investigated the effects of PIK3CA and AKT1 mutations on cell 
growth, by assessing growth assay in full serum and low serum using the previously 
described isogenic MCF7 cell line. The presence of mutant PIK3CA in MCF7-
PIK3CA provided growth advantage in these cell lines in both serum conditions 
(Figures 9A-C). The introduction of AKT1-E17K mutation on MCF7-WT with wild-
type PIK3CA resulted in an increased proliferation rate. MCF7-AKT1 grew at an 
intermediate rate between mutant and wild-type PIK3CA. We also tested the in vivo 
growth ability of these cell lines in nude mice implanted with estradiol pellets. 
PIK3CA and AKT1 mutant cells readily formed tumors at similar rates, whereas 
MCF7-WT tumor growth was slower (Figure 9D). In addition, PIK3CA and AKT1 
mutant cells stimulated greater colony formation than did wild-type PIK3CA cells 
(Figure 10A). PIK3CA and AKT1 induced activation of AKT and showed increased 
phosphorylation of serine-473 and threonine-308, as detected by immunoblot. In 
turn, AKT activation enhanced the phosphorylation of known AKT target proteins, 








Figure 9. PIK3CA and AKT1 mutations confer growth advantage in vitro and in 
vivo. A)Cells were seeded at 500 cells/well in 96-well plates in triplicate and treated 
with 10% FBS and B) 5% CSS supplemented with 5 nM β-estradiol. SRB assay 
were used to determine the viability of the cells every two days. C) Cells were 
seeded at 1,000 cells/well in 96-well plates in triplicate. Cell counting was used to 
determine the survival of the cells every two days. D) For in vivo growth of each 
genotype, six estrogen-supplemented nude mice per group were injected with 
5x10 6̂ cells suspended in matrigel. The tumor volumes were measured twice a 
week for 25 days. P-value calculated based on ANOVA: 0.1234 (ns), 0.0332 (*), 










Figure 10. PI3K pathway signaling and colony formation ability in PIK3CA and 
AKT1 mutations.A) MCF7 isogenic cell lines were treated with five different 
concentrations of palbociclib and vehicle in a ten-fold serial dilution series for 72 
hours. SRB assay was used to assess cell growth effect and the IC50 values were 
calculated using dose-effect analyzer software CalcuSyn 2.0. B) Cells were treated 
with increasing concentrations of palbociclib and vehicle for three weeks. The 
colonies were then fixed and stained with crystal violet. C) Quantification of crystal 
violet staining from cells in B using NIH ImageJ v.1.46 software. P-value calculated 
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3.2.3 PIK3CA and AKT1 mutations reduce the sensitivity of palbociclib in 
vitro 
We next examined whether PIK3CA or AKT1 mutations can impact the 
response to palbociclib. The CDK4/6 inhibitor palbociclib in combination with 
endocrine therapy has been approved by the FDA for the treatment of ER-positive, 
HER2-negative advanced breast cancer [93]. Cell growth assay and colony 
formation were performed to determine palbociclib efficacy in MCF7 cell lines with 
varying genotypes. Wild-type cells showed significant reduction in IC50 (Figure 11A) 
(p<0.0001 for PIK3CA vs WT and p=0.043 for AKT1 vs WT) and anchorage-
dependent proliferation shown by formation of fewer colonies in response to 
palbociclib treatment, but the presence of PIK3CA and AKT1 mutations conferred 
less sensitivity (Figures 11B and C). 
It is known that CDK4/6 forms a complex with cyclin D to promote cell cycle 
progression through phosphorylation and inactivation of protein RB [134]; therefore, 
we examined the effect of CDK4/6 inhibition on cell cycle. Treatment with increasing 
doses of palbociclib resulted in a prominent decrease in RB phosphorylation (serine 
807/811) in WT cells, while PIK3CA and AKT1 mutants had less decrease in pRB-
S807/811 (Figures 12A and B). Additionally, palbociclib led to a dramatic decrease 
in S and G2-M phases in WT cells, compared with mutants (Figures 12C and D) 
(p=0.015 for palbociclib vs Ctrl. In WT). These observations indicate that PIK3CA 





Figure 11. PIK3CA and AKT1 mutations show less sensitivity to palbociclib.A) 
Cells were seeded at 1,000 cells/60 mm plates in triplicate. Colonies were then 
stained with crystal violet and counted using NIH ImageJ v.1.46 software after 3 
weeks. B) Cells were grown in medium containing 10% and 1% FBS. Equal 
amounts of protein were loaded on SDS-PAGE gels and blotted with the antibodies 
shown. P-value calculated based on ANOVA: 0.1234 (ns), 0.0332 (*), 0.0021 (**), 
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Figure 12. PIK3CA and AKT1 mutations modulate RB phosphorylation and cell 
cycle progression in response to palbociclib.A) The expression level of RB 
phosphorylation (serine 807/811) in cells treated with various concentrations of 
palbociclib for 24 hours was determined by western blotting. B) Densitometric 
quantification of western blot bands was analyzed with Image Studio Lite Ver 5.2. 
Protein levels were normalized to β-Actin. C) Cell were treated with 100 nM of 
palbociclib for 24 hours. The cells were then fixed and stained with propidium iodide 
and the cell abundance in different phases of cell cycle were analyzed with flow 
cytometry. D) Bar graphs show the quantification analysis for the significance of 
changes in G2-M and S phases. All data mean ± SD are indicated using triplicate 
samples of each representative experiment. P-value calculated based on ANOVA: 
0.1234 (ns), 0.0332 (*), 0.0021 (**), 0.0002 (***) and < 0.0001(****). 
3.3 SUMMARY 
It has been noted by others that PI3K and MAPK signaling pathways cross- 
talk with each other[135]. Mutant PIK3CA led to a marked increase in MAPK-
regulated kinase ERK1/2 phosphorylation. However, the presence of AKT1-E17K in 
MCF7 cells with wild-type PIK3CA did not affect ERK1/2 phosphorylation level, 
suggesting that such interaction is cell type specific. Despite stimulation of PRAS40, 
PIK3CA and AKT1 did not induce phosphorylation of downstream targets, including 
p70S6K and ribosomal protein S6 (pS6). Overall, increased PI3K/AKT signaling 
activity was observed in the presence of full serum—more in mutant cell lines than 
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wild-type MCF7—but it did not restore the phosphorylation level of downstream 
targets in MCF7-WT to the same level as found in mutant cells (Figure 10B).   
The PI3K/AKT pathway is one of the most frequently mutated signaling 
pathways in breast cancer and drives tumor survival, genomic instability, motility, 
and progression [115]. Alterations in the genes encoding several components of the 
PI3K/AKT pathway, such as mutations of PIK3CA and AKT1 genes, often occur in 
ER-positive breast cancer [136]. In our isogenic model system, PIK3CA and AKT1 
conferred growth advantage and enhanced the in vivo tumorigenic properties of 
luminal breast cancer (Figures 9A-C). This data also suggest a bona fide oncogenic 
function for AKT1-E17K mutation. In lung epithelial cells, AKT1-E17K mutation has 
been shown to have an oncogenic role due partly to its involvement in CDK inhibitor 
p27 regulation [137]. Understanding the predictive biomarker value of specific PI3K 
pathway driver mutations can enhance the response to current and future novel 
targeted therapies in ER-positive luminal breast cancer. 
The CDK4/6 inhibitors have profoundly transformed the therapeutic index of 
HR-positive, HER2-negative advanced breast cancer. They have provided survival 
benefits and substantial efficacy in combination with endocrine therapies. In the 
PALOMA-1 and PALOMA-2 trials, the addition of palbociclib enhanced median PFS, 
compared with letrozole alone [100, 138]. Further, patients who received palbociclib 
with fulvestrant in PALOMA-3 had a longer PFS than those who were treated with 
fulvestrant plus placebo [97]. Despite the clinical benefits of CDK4/6 inhibitors in the 
treatment of ER-positive breast cancer, acquired resistance to CDK4/6 inhibition 
limits their efficacy. Ongoing preclinical studies are currently investigating various 
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pathways potentially responsible for resistance. Given the heterogeneity nature of 
HR-positive breast cancer, exploring the mechanisms of resistance requires 
acknowledgment of the tumor’s genomic background. 
We demonstrated that PIK3CA and AKT1 mutant cell lines are less 
responsive to the cytotoxicity effect of palbociclib and exhibited higher IC50, 
compared with WT cells (Figure 11A). Exposure to different concentrations of 
palbociclib induced markedly greater inhibition of proliferation and colony formation 
in WT cells (Figures 11B and C). In addition, after treatment with palbociclib, the 
protein expression level of RB phosphorylation was remarkably decreased, whereas 
PIK3CA and AKT1 mutant cell lines had a lesser reduction (Figures 12A and B). 
More significant G2-M and S phase arrests were observed in WT than in mutant cell 
lines in response to palbociclib (Figures 12C and D). Taken together, these results 
showed that the presence of either PIK3CA or AKT1 mutation is sufficient enough to 
reduce palbociclib efficacy. This is an important finding that can help in addressing 
CDK4/6 inhibition resistance and optimize palbociclib use in the clinical treatment of 














CHAPTER 4:  SYNTHETIC LETHALITY SCREENING IDENTIFIED DDR1 AS 
SYNTHETIC LETHAL PARTNER OF PALBOCICLIB IN PIK3CA AND AKT1 
MUTANT ER-POSITIVE BREAST CELL LINES 
CHAPTER 4: SYNTHETIC LETHALITY SCREENING IDENTIFIES DDR1 AS A 
SYNTHETIC LETHAL PARTNER OF PALBOCICLIB IN PIK3CA AND AKT1 
MUTANT ER-POSITIVE BREAST CANCER CELL LINES 
 
4.1 INTRODUCTION 
The cross talk between CDK4/6 and PI3K pathways described in the literature 
provided a rationale for combined targeting of the CDK4/6-PI3K axis [139, 140]. 
Likewise, the combination of CDK4/6 and PI3K inhibitors induced synergistic 
interaction, leading to greater tumor regression and improved outcome in PIK3CA 
mutant breast tumor [118, 121]. In preclinical and clinical studies, prolonged 
exposure to CDK4/6 inhibition provoked adaptive resistance in ER-positive breast 
cancer [118, 141]. Despite numerous attempts to identify biomarkers responsible for 
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resistance or predict response to CDK4/6 inhibitors, little has benefited the clinical 
outcomes of breast cancer. 
Given the available preclinical and clinical data, the compensatory activation 
of the PI3K oncogenic pathway might be a relevant candidate to induce acquired 
resistance to CDK4/6 inhibition [118]. Meanwhile, previous results (Chapter 3) 
showed that the presence of PIK3CA and AKT1 in an isogenic model system 
decreased the in vitro efficacy of palbociclib. Therefore, the goal of this chapter was 
to identify ways to overcome palbociclib resistance induced by PIK3CA/AKT1. Given 
the frequent somatic mutations in the PI3K pathway, finding additional targets 
through identifying other potential survival pathways that take advantage of PIK3CA 
and AKT1 driving mutations will enhance the clinical benefit of palbociclib as well as 
the current therapy of ER-positive breast cancer. 
We have used a human kinome shRNA library targeting a variety of cancer-
related kinases to determine potential targets that only affect the survival in cells with 
PIK3CA or AKT1 mutations when treated with palbociclib. Further, we validated the 
candidate genes to identify the most effective combinational partner to enhance 
palbociclib efficacy in cells harboring PIK3CA and AKT1 mutations. The synthetic 
lethality experiment can help us design rational combination therapies that take 
advantage of PIK3CA and AKT1 driving mutations to be used in clinical trials for 




4.2.1 Using a pooled shRNA library and dropout selection screening to 
identify potential synthetic lethal genes in response to palbociclib 
To determine ways for improving the response of ER-positive breast cells to 
CDK4/6 inhibition, we conducted a synthetic lethality screen in MCF7 cells with wild- 
type or mutant PIK3CA or AKT1 mutant status. For this we used a lentiviral library 
consisting of 5,500 barcoded shRNA constructs, targeting 530 cancer-related human 
kinases. Because different cancer cell lines exhibit differential sensitivity to lentiviral 
transduction, we determined the MOI required to transduce 20% of the cells (Figure 
7). When the number of infected cells is at or below 20%, each transduced cell 
expresses a single shRNA with good approximation. The transduced cells were 
treated with palbociclib for 2 weeks before isolating the genomic DNA (gDNA) to 
analyze the sequence of integrated shRNAs. A pellet of pooled cells for each cell 
line was frozen to be used as a reference for confirming equal representation of 
each shRNA before starting palbociclib treatment (Figure 13A). 
Negative screen analysis was performed by high-throughput quantitative RT-
PCR, and a gene summary was generated by using redundant shRNA activity (RSA) 
scoring, which provides a ranking of each gene in the screen. Using log 10 p-value 
of 0.05 (-1.3) as the cut-off point to define significant hits, we compared the top 
scoring genes in the presence of drug to vehicle-treated cells to identify target genes 
that provide a selective disadvantage in the presence of palbociclib (Figures 13B 
and Table 4). 
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We prioritized the top identified hits in each group on the basis of prognostic 
and therapeutic implications and the clinical relevance of genes in breast cancer. In 
addition, we employed previous knowledge of the associations of kinases with ER 
status and functional role in the PI3K/AKT pathway to select the top potential 
synthetic lethal targets that were mainly involved in cell cycle regulation and 









                         
                             
                              




Figure 13. Transduction of MCF7 cell lines with lentiviral shRNA library and 
negative selection screeningA) Schematic depiction of the pooled shRNA 
screening workflow. MCF7 isogenic cells were transduced with human kinome 
lentiviral library consists of 5500 barcoded shRNA constructs targeting 530 human 
kinases and treated with palbociclib in addition to vehicle for two weeks. B) Negative 
screen analysis was assessed for the indicated cell lines by high-throughput 
quantitative RT-PCR to create gene summary using redundant shRNA activity 
scoring (RSA). The orange dots indicate top scoring hits in the presence of 
palbociclib treatment based on -1.3 cut-off point (log10 of 0.05). DDR1, a common 
top hit in PIK3CA and AKT1, is distinguished with an arrow. 
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Table 4. List of the candidate genes that confer a selective disadvantage in the 
presence of palbociclib.Negative screen analysis was assessed by high-
throughput quantitative RT-PCR using the MCF7 isogenic cell lines transduced with 
hKinome lentiviral library. The identified candidate synthetic lethal genes in the 
presence of palbociclib treatment using p-value < 0.05 are listed for WT (wild-type), 





    
 
 
Table 5. List of the selected potential synthetic lethal genes for palbociclib 
treatment. Genes were prioritized on the basis of their functional and clinical 
associations in breast cancer.  
4.2.2 Synthetic lethality screening identifies DDR1 as a synthetic lethal 
partner of palbociclib in PIK3CA and AKT1 mutant ER-positive breast cancer 
cell lines 
Using shRNA knockdown and SRB proliferation assay, we examined the 
candidate hits, including DDR1, MTOR, NEK8, PRKCD, STK31, and TLK2. The 
results indicated that silencing DDR1 by using two different shRNAs inhibited the 
growth of PIK3CA and AKT1 mutant and wild-type ER-positive cell lines in vitro 
(Figure 14A). However, the mutant DDR1 knockout cells were more sensitive to the 
inhibitory effect of palbociclib, showing that DDR1 silencing selectively sensitized 







Figure 14. shRNA library screening identifies DDR1 as a candidate synthetic 
lethal partner for palbociclib in both PIK3CA and AKT1 mutant cell linesA) 
Cells were infected with non-targeting control shRNA (shRNA-NTC) and two 
different shRNAs targeting DDR1. Following 48 hours puromycin selection, cells 
were seeded at 1,000 cells/well in 96-well plates in triplicate. SRB assay was used 
to determine the viability of the cells every two days. B) The puromycin selected 
cells in A were treated with vehicle (DMSO) or 100 nM palbociclib for 72 hours. Cell 
survival was analyzed using SRB colorimetric assay. All data mean ± SD are 
indicated using triplicate samples of each representative experiment. P-value 




4.2.3 Correlation between DDR1 expression and ER status in a cohort of 
breast cancer patients  
To determine the correlation between DDR1 and ER expression level, we 
analyzed a cohort of breast cancer patients from The cancer Genome Atlas (TCGA), 
and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) 
datasets. The analysis showed that DDR1 mRNA level is significantly higher in ER-
positive versus ER-negative tumors (p=4.7e-09 for TCGA and p=1e-19 for 
METABRIC) (Figures 15A and B). In addition, 56% (256/455 in TCGA) and 57% 
(492/859 in METABRIC) of ER-positive samples were high-DDR1 tumors, whereas 
33% (54/164 in TCGA) and 28% (79/2282 in METABRIC) of ER-negative tumors 
had high-DDR1 expression, indicating that DDR1-high tumors are more frequent in 
ER-positive patients (p=1.99e-07 for TCGA and p=2.2e-16 for METABRIC) (Figures 
15C and D). 
To further corroborate this finding, we interrogated data sets for different 
breast cancer subtypes and observed that HR-positive patients had higher DDR1 
expression than did patients with TNBC (p=1.5e-05 for TCGA and p=2.5e-19 for 
METABRIC) (Figures 16A and B). The tendency toward co-occurrence of high-
DDR1 expression and PIK3CA/AKT1 mutations in ER-positive patients was not 
consistent across different datasets, whereas AKT1 mutation occurs at a low 






              
 
Figure 15. The correlation between DDR1 expression and ER status, in a 
cohort of breast cancer patients using TCGA and METABRIC dataset.A-B) 
RNA-seq. expression data was used to determine the level of DDR1 expression in 
ER-positive and ER-negative patients in TCGA (A) and METABRIC (B) dataset C-D) 
The Box and whisker plots show the frequency of DDR1 expression in ER-positive 
and ER-negative patients using the RNA-seq. expression data in TCGA (C) and 
METABRIC (D) datasets. Student’s t-test was used to examine if the mean of the 
two groups were significantly different. The whiskers indicate the max and min 
values. The samples were arranged by the expression of DDR1 from high to low. 
The top 30% samples are classified as ”high”, and the bottom 30% samples are 
classified as ”low”. Fisher’s Exact test was used to examine the frequency of 
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high/low DDR1 expressed samples in patients based on ER-status. Student’s t-test 
was used to examine if the mean of the two groups were significantly different. The 







                          
 
Figure 16. The expression of DDR1 in different breast cancer subtypes and ER-
positive group with PIK3CA/AKT1 mutations using TCGA and MRTABRIC 
dataset. A-B) One-way ANOVA was used to determine whether there are any 
statistically significant differences between the means of HR-positive, HER2-positive 
and TNBC groups. C-E) Figures showing the expression of DDR1 in ER-positive 
patients with or without PIK3CA or AKT1 mutations. Student’s t-test was performed 
to calculate the p-values. There was only one ER-positive patient with AKT1 
mutation in TCGA data set, so the comparison was excluded.   
 
4.3 SUMMARY 
On the basis of the screening results, we identified and functionally validated 
that discoidin domain receptor 1 (DDR1) is required for the survival and proliferation 
of PIK3CA and AKT1 mutant cells and selectively sensitizes these cells to 
palbociclib. DDR1, a collagen-activated tyrosine kinase, is amplified in various types 
of tumor, including 14% of metastatic breast cancers and has a critical role in cell 
attachment, survival, and proliferation [142]. Moreover, recent data suggest that 
DDR1 functions as a regulator of cell response to hormones, growth factors, and 
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extracellular signals in breast cancer [143]. In fact, our analysis of breast cancer 
patients from the TCGA and METABRIC datasets showed that DDR1 expression 
level is significantly higher in ER-positive tumors than in TNBC tumors. In this study, 
we have shown that DDR1 depletion inhibited cell proliferation and decreased 
clonogenicity while targeting DDR1 suppressed tumor growth. These findings 
support the potential role of DDR1 as a therapeutic target for the treatment of ER-




CHAPTER 5:  DDR1 SUPPRESSION INHIBITED PROLIFERATION AND 
SELECTIVELY SENSITIZED PIK3CA/AKT1 MUTANT CELLS TO 
PALBOCICLIB TREATMENT…… 
CHAPTER 5: DDR1 SUPPRESSION INHIBITS PROLIFERATION AND 




5.1.1 Structure, activation, and function of DDR1 
Discoidin domain receptors (DDRs) are type I transmembrane RTKs that, 
unlike other RTKs, are specifically activated in response to collagens, a major 
component of the extracellular matrix (ECM) [144]. DDR1 and DDR2 are the two 
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types of DDR kinases that display distinct-collagen binding specificity. DDR1 
preferentially binds to collagens type I–VI and VIII, whereas DDR2 is activated by 
collagens type I, III, and X [145-147]. The human DDR1 gene is located on 
chromosome 6 (6p21.3) and encodes five different DDR1 isoforms as a result of 
alternative splicing. DDR1a, DDR1b, and DDR1c are full-length receptors with 
functional enzymatic activity, whereas DDR1d and DDR1e are inactive kinases due 
to frame-shift and truncation genomic alterations [148]. The DDR2 gene maps to 
chromosome 1 and generates a single isoform of the receptor. DDR1 is composed 
of various structural domains, including: the N-terminal discoidin (DS) domain, DS-
like domain, extracellular juxtamembrane region (EJXM), transmembrane segment 
(TM), intracellular juxtamembrane region (IJXM), kinase domain (KD), and a short C-
terminal domain at the very end (Figure 17) [149, 150]. 
DDR1 is involved in the regulation of mammary gland development and plays 
a role in cellular processes such as survival, proliferation, migration, invasion, matrix 
remodeling, and EMT [151-154]. After collagen binding, the cytosolic kinase domain 
of DDR1 becomes phosphorylated at several residues, leading to downstream 
signaling activation [155]. Collagen-induced DDR1 phosphorylation occurs several 
hours after ligand stimulation and remains active for as long as a day, showing 
significantly slow kinetics compared with other RTKs [145, 156]. Phosphorylated 
sites in the kinase domain are able to bind to a number of adopter proteins, such as 
Src homology 2 (SH2) domain containing protein, [157], focal adhesion kinase (FAK) 
[158], C-terminal Src kinase (Csk) [159], p85 subunit of PI3K [160, 161] and proline-
rich tyrosine kinase (pyk2) [158]. Some proteins, like Notch1 [162] and E-cadherin 
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[163], are able to interact with DDR1 regardless of its collagen-induced 
phosphorylation. In mouse embryonic stem cells (mESCs), collagen I binds to and 
activates both DDR1 and α2β1 integrin. DDR1 induces Ras, PI3K/AKT, and ERK 
signaling cascade, while α2β1 integrin triggers Notch/Gli-1 upregulation. These 
events consequently activate Bmi-1 leading to RB inhibition and cell cycle 
progression in mESCs [164].  
 
 
Figure 17. Structural domains of five different DDR1 isoforms. DDR1a, DDR1b 
and DDR1c are active kinase receptors. DDR1d and DDR1e are kinase deficient 
receptors. DS: discoidin domain; DS-like: discoidin-like domain; EJXM: extracellular 
juxtamembrane region; TM: transmembrane segment; IJXM: intracellular 




5.1.2 DDR1 as a target in breast cancer 
Aberrant expression of DDR1 has been shown to promote tumor growth in 
various human cancers, including breast, lung, gastric, glioma, and ovary [165-168]. 
In breast cancer, DDR1 has been shown to promote invasion and survival and to 
regulate EMT and apoptosis in a microenvironment-dependent manner [160, 169, 
170]. In KRAS-mutant lung adenocarcinoma, the co-inhibition of DDR1 and Notch 
enhanced tumor growth suppression [165], whereas high DDR1 expression served 
as a survival factor in p53 wild-type breast cancer cells [152]. These evidences 
suggest that DDR1 has a complex role in breast cancer functions, as either an anti-
proliferating or pro-survival factor. 
The differential effects of DDR1 expression in breast cancer may be impacted 
by the presence of other genomic alterations and hormonal receptor status. 
Collagen is the most abundant protein in ECM, and the unique interaction between 
DDR1 and collagen plays an important role in tumor progression. Given the 
considerable gap in our knowledge of DDR1 functional behavior in breast cancer, 
more context-dependent investigation is required to understand DDR1 contribution 
to breast cancer progression. In the previous chapter, DDR1 was identified as a 
potential synthetic lethal partner that differentially enhanced palbociclib sensitivity in 
PIK3CA and AKT1 mutant cells. We also reported a higher DDR1 mRNA expression 
in luminal ER-positive breast tissues. Therefore, DDR1 expression and its 
proliferation effects need to be addressed to further confirm its selective action in our 




5.2.1 Silencing DDR1 with different targeted shRNAs, and validating 
knockdown efficiency  
Numerous studies have shown the pro-survival role of DDR1 in breast cancer 
[169, 171].  DDR1 has been implicated in the induction of EMT and functionally 
interacts with growth signaling receptors to positively modulate invasion and survival 
[169, 172, 173]. These results indicate that DDR1 is an important target for breast 
cancer and has a wide role in regulating cell response to growth factors and 
hormones. Therefore, to verify the DDR1 selective requirement in PIK3CA/AKT1 
mutant cells, we analyzed the effect of suppressing DDR1 and palbociclib treatment 
on cell viability and proliferation. Cells were infected with non-targeting control 
shRNA and three different DDR1-targeting shRNAs. After knockdown, efficiency was 
confirmed by using immunoblot and qRT-PCR (Figures 18A and B). Interestingly, 
the DDR1 protein and mRNA levels were higher in PIK3CA/AKT1 mutant cells, 
suggesting a correlation between DDR1 expression and palbociclib sensitivity 



















Figure 18. DDR1 protein and mRNA level in shRNA-induced DDR1 silencing 
cell lines.A) MCF7 cell lines were infected with non- targeting control shRNA 
(shNTC) and three different shRNA targeting DDR1. After puromycin selection for 72 
hours, the DDR1 protein level was determined by western blotting. B) qRT-PCR 
results quantifying DDR1 mRNA level in DDR1 knockdown relative to control 
(shNTC) in each cell lines. C) qRT-PCR analysis of DDR1 mRNA level was 
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evaluated in PIK3CA and AKT1 mutant cells relative to WT cells. Normalization was 
done using human GAPDH as housekeeping control gene.  
 
 
5.2.2 DDR1 suppression inhibits proliferation and selectively sensitizes 
PIK3CA/AKT1 mutant cells to palbociclib treatment 
To verify the selective sensitivity of PIK3CA/AKT1 mutant cells on cell viability 
and proliferation in response to DDR1 suppression and palbociclib treatment, the 
DDR1 knockdown cells were treated with vehicle or palbociclib for 3 weeks. We 
observed a remarkable decrease in colony formation in all shRNA-mediated DDR1 
silencing cells, regardless of their genomic backgrounds, indicating that DDR1 plays 
a crucial role in cell survival. The addition of palbociclib induced a significant growth 
reduction in DDR1 knockdown PIK3CA and AKT1 mutant cells compared with 
control, whereas DDR1 knockdown WT cells exhibited a growth inhibition rate 
similar to control (Figures 19A and B). 
We had shown earlier that PIK3CA and AKT1 mutations decreased 
palbociclib sensitivity; therefore, we examined whether DDR1 silencing enhances 
their response. Cell cycle analysis by flow cytometry confirmed that, in 
PIK3CA/AKT1 mutant cells, DDR1 knockdown combined with palbociclib induced a 
greater decrease in G2-M and S phases, whereas no significant change was 
observed in the shRNA control cells treated with palbociclib. There was no 
difference in palbociclib-induced cell cycle inhibition between DDR1 knockdown and 
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control shRNA in WT cells (Figures 19C and D). This indicates that DDR1 silencing 













                 
 
Figure 19. Silencing DDR1 sensitizes PIK3CA and AKT1 mutant cells to 
palbociclib treatment. A) DDR1 knockdown cells were treated with 50 nM of 
palbociclib and vehicle for three weeks. The colonies were then fixed and stained 
with crystal violet. B) Quantification of crystal violet staining from cells in A using NIH 
ImageJ v.1.46 software. C-D) DDR1 knockdown cells were treated with 100 nM of 
palbociclib for 24 hours. The cells were then fixed and stained with propidium iodide 
and the cell abundance in different phases of cell cycle were analyzed with flow 
cytometry. Bar graphs show the quantification analysis for the significance of 
changes in G2M (C) and S (D) phases. All data mean ± SD are indicated using 
triplicate samples of each representative experiment. P-value calculated based on 






shRNA screening analysis identified DDR1 as a novel synthetic lethal partner 
that differentially augmented palbociclib sensitivity in PIK3CA and AKT1 mutant cell 
lines. Notably, DDR1 expression level was higher in PIK3CA/AKT1 mutant cells, 
indicating the role of DDR1 in growth enhancement and increased proliferation 
observed in those cell lines. It also suggests a correlation between DDR1 expression 
level and reduced palbociclib sensitivity. Increased DDR1 expression may potentially 
benefit PIK3CA/AKT1 mutations to resist the anti-proliferation effect of palbociclib. 
To evaluate the effect of DDR1 suppression on colony formation and cell cycle 
progression, we silenced DDR1 using three different shRNAs All three DDR1-
targeting shRNAs induced greater than 70% reductions in both protein and mRNA 
level. DDR1 suppression inhibited colony proliferation of PIK3CA and AKT1 mutant 
and wild-type lines while selectively providing synergistic effect with palbociclib in 
mutant cell lines (Figures 19A and B) consistent with the previous survival assay 
results. 
CDK4/6 form a complex with cyclin D1 to hyperphosphorylate and inactivate 
RB, allowing entry to S phase and cell cycle progression [174, 175]. CDK4/6 
inhibition blocks RB phosphorylation and subsequently leads to cell cycle arrest at 
G1, reducing the cell population at S phase [176]. Palbociclib treatment significantly 
inhibited the cell cycle at S phase in PIK3CA and AKT1 mutant cells expressing 
three different DDR1-targeting shRNAs but not in the cells with control shRNA 
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(Figure 19D). Silencing DDR1 did not improve palbociclib-induced cell cycle arrest in 
WT cells. Hence, DDR1 suppression induces cell cycle inhibition effect of palbociclib 
reduced by PIK3CA and AKT1 mutations. These data further support the role of 
DDR1 in enhancing palbociclib sensitivity in ER-positive breast cancer with PIK3CA 
or AKT1 mutations. Investigating molecular signaling alterations in response to 
DDR1 inhibition will help elucidate the functional role of DDR1 as a novel target in 
breast cancer.  
 


















CHAPTER 6:  DDR1 INHIBITION WITH 7RH SENSITIZED PIK3CA AND 
AKT1 MUTANT CELLS TO PALBOCICLIB TREATMENT BY INDUCING CELL 
CYCLE ARREST 
CHAPTER 6: DDR1 INHIBITION WITH 7RH SENSITIZES PIK3CA AND AKT1 




Targeting DDR1 by using selective available pharmacological agents is 
another approach to further validate the synergistic effect of DDR1 and CDK4/6 
combined inhibition. Generally, there are two types of non-covalent kinase inhibitors. 
Type I competes with ATP for binding to the kinase active site (ATP-binding pocket) 
and maintains an active conformation, whereas type II occupies the allosteric site 
stabilizing an inactive kinase conformation [177, 178]. Among the FDA-approved 
small-molecule protein kinase inhibitors, dasatinib, nilotinib, imatinib [179], and 
ponatinib [180] potently suppress DDR1 activity while strongly inhibiting a panel of 
other kinases (Table 6 and Table 7). These multi-targeted drugs were rationally 
developed for targeted therapy of chronic myeloid leukemia (CML) with Bcr-Abl 
tyrosine kinase alterations. 
Given the emerging role of DDR1 as a potential anti-cancer target, several 
compounds have been discovered to selectively inhibit DDR1 kinase activity, with 
less efficacy against other kinases (Table 7) [181-183]. A series of benzamide 
compounds has been reported to have encouraging selective DDR1 inhibition 
effects. The two most promising benzamide compounds, 7rh and 7rj, were shown to 
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inhibit the kinase function of DDR1, with IC50 values of 6.8 nM for 7rh and 7 nM for 
7rj [181]. They displayed significantly less efficacy against kinases such as DDR2 
and Bcr-Abl. Moreover, 7rh and 7rj exhibited a good in vivo pharmacokinetic profiles 
with half-lives of 15.5 hours and 9.8 hours, respectively.  
 
                    
Table 6. FDA-approved non-selective oral DDR1 and DDR2 inhibitors. The 
kinases targeted by each inhibitor are listed in the columns.  
 
The PI3K/AKT pathway positively regulates survival by activating the proteins 
with critical roles in cell cycle progression, such as cyclin D1 [139]. Therefore, DDR1 
inhibition may differentially impact the protein expression of known palbociclib 
effectors in PIK3CA and AKT1 mutant cells. We used 7rh (DDR1 selective 
pharmacological inhibitor) in combination with palbociclib to further validate the 
synergistic effect of DDR1 and CDK4/6 combined inhibition on colony-forming ability 
and cell cycle progression. To determine the molecular signaling responsible for 
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improving palbociclib response in the presence of DDR1 inhibitor, we examined the 
protein levels of known palbociclib effectors as well as other potential proteins 
involved in cell signaling.   
 
    
Table 7. Reported selective and non-selective DDR1 and DDR2 inhibitors. The 
half-maximal inhibitory concentration (IC50) values against DDR1 and DDR2 and 




6.2.1 DDR1 and CDK4/6 co-inhibition induces a synergistic response and 
anti-proliferation effect in PIK3CA and AKT1 mutant cells  
To develop a therapeutic strategy that would enhance palbociclib sensitivity 
reduced by PIK3CA and AKT1 mutations, we used 7rh benzamide (Figure 20A), an 
orally available ATP-competitive selective DDR1 inhibitor with potent DDR1 
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inhibition in preclinical models [184]. Cells were treated with varying concentrations 
of 7rh (0.01–100 µM) and palbociclib (0.001–10 µM) as single and combined agents 
for 72 hours. All cell lines showed decreased survival to 7rh in a dose-dependent 
manner, and the addition of palbociclib induced synergy with stronger effect in 
PIK3CA and AKT1 mutant cells with consistent CI values <1(Figure 20B). We 
performed clonogenic assay to further assess growth inhibition in response to 7rh, 
palbociclib and their combination at various doses. Compared with control, MCF7-
WT exhibited a robust growth inhibition in all treatment groups. However, 
combinations at various doses demonstrated a significant growth reduction 








                               
 
 





                   
Figure 20. DDR1 and CDK4/6 co-inhibition induces more sensitivity and anti-
proliferation effect in PIK3CA and AKT1 mutant cells. A) Structure of 7rh 
benzamide compound: (3-(2-(pyrazolo(1,5-a)pyrimidin-6-yl)-ethynyl). B) MCF7 
isogenic cell lines were treated with five different concentrations of 7rh, palbociclib, 
the combination of 7rh and palbociclib or vehicle in a ten-fold serial dilution series for 
72 hours. SRB assay was used to assess cell growth effect and the CI values were 
calculated using dose-effect analyzer software CalcuSyn 2.0. C-E) Cells were 
treated with increasing concentrations of 7rh, palbociclib or the combination of 7rh 
and palbociclib for three weeks. The colonies were fixed and stained with crystal 
violet then counted using NIH ImageJ v.1.46 software. 
 
 
6.2.2 DDR1 inhibition enhances palbociclib-induced cell cycle arrest of 
PIK3CA and AKT1 mutant cells 
We next examined the effect of palbociclib and 7rh treatment on cell cycle 
progression. The cells were treated for 24 hours with 7rh or palbociclib alone or with 
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a combination of both compounds, then harvested and subjected to flow cytometric 
analysis. As expected, palbociclib dramatically decreased the population of WT cells 
in S and G2-M phases, whereas the reduction was modest in PIK3CA and AKT1 
mutant cells. The addition of 7rh to palbociclib produced smaller percentages of 
PIK3CA and AKT1 mutant cells in S and G2-M phases as compared with single 
agents, suggesting cell cycle arrest. However, WT cell percentages remained 
unchanged (Figures 21A-B). To further explore the enhanced effect of DDR1 
inhibitor on palbociclib induced cell cycle inhibition, cells were treated with 7rh, 
palbociclib, or the combination of both drugs for 24 hours. 
Immunoblot analysis of known palbociclib effectors, pRB and FoxM1, [185] in 
addition to other cell cycle regulators was performed. The results showed that both 
7rh and palbociclib individually caused differential decreases in RB phosphorylation, 
FoxM1, and PLK1 levels in all cell lines, but the combination yielded a greater 
reduction in only PIK3CA and AKT1 mutant cells (Figure 21C). Consistent with the 
work of others [186, 187], the level of c-Myc, a critical positive cell cycle regulator, 
decreased in all treatment groups while cyclin D1 increased. These results suggest 
that the presence of PIK3CA and AKT1 mutations prevent sufficient reduction in RB 
phosphorylation in response to palbociclib, and 7rh can further suppress the residual 
phosphorylation in the context of co-treatment. Therefore, full suppression of cell 















           
 
Figure 21. DDR1 inhibition enhances palbociclib-induced cell cycle arrest of 
PIK3CA and AKT1 mutant cells. A-B) Cell were treated with 100 nM of palbociclib, 
1µM of 7rh or the combination of both drugs for 24 hours. The cells were then fixed 
and stained with propidium iodide and the cell abundance in different phases of cell 
cycle were analyzed using flow cytometry. Bar graphs show the quantification 
analysis for the significance of changes in G2-M (A) and S (B) phases. C) MCF7 
isogenic cell lines were treated with 1 µM of 7rh, 100 nM of palbociclib or the 
combination of 7rh and palbociclib for 48 hours. The expression levels of cell cycle-
associated proteins were analyzed by western blotting. All data mean ± SD are 
indicated using triplicate samples of each representative experiment. P-value 






6.2.3 DDR1 inhibition enhances palbociclib-induced cell cycle arrest of ER-
positive breast cancer cell lines with PIK3CA mutations 
To further evaluate the synergistic effect of DDR1 and CDK4/6 co-inhibition, 
we examined KPL-1 (PIK3CA-E545K mutation), BT483 (PIK3CA-E542K mutation), 
and T47D (PIK3CA-H1047R mutation) ER-positive cell lines. Likewise, SRB cell 
proliferation and colony formation assays revealed that 7rh potently inhibited the 
growth of other ER-positive, HER2-negative luminal breast cancer cells with PIK3CA 
mutations (KPL-1, BT483, and T47D) in a dose-dependent manner and suppressed 
anchorage-dependent growth. The combination of palbociclib with 7rh to induce 
DDR1 inhibition further decreased colony-forming ability and induced palbociclib 
sensitivity in KPL-1 and BT483 cells but not in T47D cells, as shown by clonogenic 
and SRB assays (Figures 22A and B).  
To investigate the combined effect of 7rh and palbociclib on cell cycle 
signaling in KPL-1 and BT483 cell lines, the relevant protein expression levels were 
evaluated by using western blotting. Notably, dual treatment with 7rh and palbociclib 
markedly decreased the protein expression levels of pRB, PLK1, and RRM2, 
compared with 7rh or palbociclib alone (Figure 22C). These results indicated that the 
cell cycle signaling pathway was significantly suppressed after treatment with 7rh 





                
 
              
 
Figure 22. The effect of DDR1 and CDK4/6 co-inhibition in ER-positive PIK3CA-
mutated breast cancer cell lines. A) KPL-1, BT483, and T47D cell lines were 
treated with five different concentrations of 7rh, palbociclib, the combination of 7rh 
and palbociclib and vehicle in a ten-fold serial dilution series for 72 hours. SRB 
assay was used to assess cell growth effect and the CI values were calculated using 
dose-effect analyzer software CalcuSyn 2.0. B) Cells were treated with 7rh, 
palbociclib or the combination of 7rh and palbociclib for three weeks. The colonies 
were fixed and stained with crystal violet then counted using NIH ImageJ v.1.46 
software. C) KPL-1, BT483, and T47D cell lines were treated with 1 µM of 7rh, 100 
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nM of palbociclib or the combination of 7rh and palbociclib for 48 hours. The 





Treatment with 7rh or palbociclib as a single agent decreased RB 
phosphorylation and, FoxM1 and PLK1 levels in all ER-positive breast cancer cell 
lines; combination treatment reduced PIK3CA and AKT1 mutant cells in all but the 
T47D cell lines. A study has shown that exon 9 PIK3CA mutations (E545K and 
E542K) in the helical domain are affiliated with AKT1 activation, which is essential 
for E2-dependent ERα signaling, whereas exon 20 PIK3CA mutation (H1047R) in 
the kinase domain impacts both AKT1 and AKT2 activations [188]. Similarly, 
pathological features analysis of clinical data revealed that exon 9 PIK3CA 
mutations are common in invasive lobular carcinomas and are associated with early 
recurrence and poor prognosis; conversely, exon 20 PIK3CA mutations are seen in 
all histological types of breast tumors and are associated with optimal prognosis 
[189]. Unlike other cell lines, T47D cells have PIK3CA mutation in the kinase 
domain, which may affect their sensitivity to combined 7rh and palbociclib treatment. 
Palbociclib is expected to induce cell cycle arrest in G1-S phase through the 
inhibition of CDK4/6, which allow progression to S phase. We showed that the 
addition of 7rh to palbociclib resulted in a greater reduction of cell population in S 
phase and G2-M phase in PIK3CA and AKT1 mutant cells, compared with single 
agents. Interestingly, the protein levels of PLK1, a major regulator of G2-M 
94 
 
transition, decreased significantly in response to combined treatment. Further, 
PIK3CA and AKT1 mutant cells had a modest PLK1 reduction in response to 
palbociclib, whereas a higher level of PLK1 was detected in those cell lines than in 
WT cells. In a recent clinical study of ER-positive metastatic breast cancer, PLK1 
inhibition induced a dramatic tumor suppression in cyclin D1–driven patient-derived 
xenografts with acquired resistance to palbociclib [190]. On the basis of these 
observations, PLK1 may have a potential role in driving palbociclib resistance in ER-
positive breast cancer with PIK3CA or AKT1 mutations, and DDR1 could represent a 















CHAPTER 7:  PHENOTYPIC CHANGES FOLLOWING DIFFERENTIAL 
DDR1 ECTOPIC EXPRESSION 
CHAPTER 7: PHENOTYPIC CHANGES FOLLOWING ECTOPIC EXPRESSION 
OF WILD-TYPE AND MUTANT DDR1 
 
7.1 INTRODUCTION 
Aberrant alteration of RTKs is a common indication in all human cancers and is 
implicated in disease pathogenesis and progression. Therefore, there is a great 
effort to identify and explore the functional impacts of genomic mutations for the 
development of optimal targeted therapies. DNA mutations as a result of genomic 
instability are categorized into driver or passenger mutations based on their 
contribution to cancer development. Driver mutations that are positively selected 
during tumorigenesis provide growth advantage and initiate cancer progression. 
Passenger mutations on the other hand do not confer cancer phenotype and are not 
essential for tumor survival. Sequencing approach to identify the mutational profiles 
in cancer to determine their relevant functional consequences is essential for 
effective targeted therapies. Determining whether the genomic mutations map to 
critical residues within the tyrosine kinase domain can predict their functional impact 
on kinase activity.  
DDR1, a RTK with crucial roles in important cellular processes, has the unique 
ability to interact with ECM through collagens and to dysregulate the tumor 
microenvironment driving cancer invasion and aggressiveness [191]. Abundant 
expression of DDR1 mRNA and elevated protein levels were reported in invasive 
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ductal carcinomas and lymph node metastases [192], whereas invasive lobular 
carcinomas and most of the intermediate- to high-grade breast carcinomas exhibited 
a significant reduction in DDR1 mRNA and protein levels [193, 194]. Several DDR1 
somatic mutations mapped to various regions on the domain are reported in lung 
cancer [195] and acute myeloid leukemia (AML) [196]; however, identifying the 
potential involvement of these mutations in cancer progression requires further 
exploration. A few studies have identified DDR1 mutational status and examined its 
functional consequences in some cancer types [197], yet whether these alterations 
act as driver or passenger mutations remains unclear. In a recent clinical analysis, 
targeted sequencing of a large cohort of HR-positive breast cancer patients 
identified several DDR1 somatic mutations (Figure 23 ) that were strongly 
associated with poor outcomes (q-value=0.0003) [198]. Thus, to determine the 
transformational ability of the DDR1 mutations detected in HR-positive breast cancer 
patients (Figure 23), we overexpressed these mutations in MCF10A benign breast 
epithelial cell line. Several growth assays were performed to examine the 







          
Figure 23. Mutation profile and frequency plot for DDR1 transcript. The plot 
illustrates all non-silent mutations for DDR1. The DDR1 (RefSeq ID: NM_013994) 
domains are indicated below the schematic diagram. The ECD (extracellular 
domain), TM (transmembrane domain), and kinase domain are depicted as green, 
red, and orange bars respectively. Note, in the mapping from Ensembl to RefSeq 
annotation, the DDR1 variant annotation may have changed or been lost, despite 
selecting the most similar representative transcript possible. (Adopted with 
permission from: Griffith, O.L., et al., Author Correction: The prognostic effects of 





7.2.1 Phenotypic changes following ectopic expression of DDR1 in MCF10A 
benign breast epithelial cells 
To determine the transformational ability of DDR1, the MCF10A benign breast 
epithelial cell line was selected to overexpress DDR1 and control vector. After DDR1 
ectopic expression, MCF10A overexpressing DDR1 showed enhanced proliferation 
and significant increase in clonogenic growth, compared with the control cells 
(Figures 24A and B). Consistently, we also observed induction of anchorage-
independent growth in MCF10A cells after DDR1 overexpression, as shown by soft-
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agar colony formation assay (Figure 24C). MCF10A control cells were not able to 
form a soft-agar colony. DDR1-overexpressing MCF10A cells exhibited an increase 
in RB phosphorylation and c-Myc levels in response to DDR1 overexpression 
(Figure 24D). These results suggest a potential role for DDR1 in growth 
enhancement through induction of cell cycle. To test whether DDR1 increases cell 
growth and contributes to cell cycle inhibition sensitivity, we treated MCF10A cells 
with 7rh and palbociclib after DDR1 overexpression by using SRB growth assay. 
Interestingly, MCF10A cells overexpressing DDR1 displayed more sensitivity to 7rh 
(p=0.005) but not to palbociclib (p=0.038), compared with parental cells (Figure 











Figure 24. Phenotypic changes following ectopic expression of DDR1 in 
MCF10A benign breast epithelial cells. A) MCF10A cells were infected with empty 
vector (EV) and wild-type DDR1 constructs containing RFP tag. Following 48 hours 
puromycin selection, cells were seeded at 500 cells/well in 96-well plates in 
triplicate. SRB assay was used to determine the survival of the cells every two days. 
B) The cells were seeded at 500 cells/60 mm plates in triplicate. Colonies were then 
stained with crystal violet and counted using NIH ImageJ v.1.46 software after 3 
weeks. C) Soft agar assay images of the MCF10A cells after four weeks of 
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incubation. Colonies are indicated by the arrows. D) The expression levels of cell 
cycle-associated proteins were analyzed by western blotting after DDR1 
overexpression in MCF10A cells. E) Cells were treated with five different 
concentrations of 7rh, palbociclib or the combination of both drugs for 72 hours. SRB 
assay was used to assess cell growth effect and the IC50 values were calculated 
using dose-effect analyzer software CalcuSyn 2.0. All data mean ± SD are indicated 
using triplicate samples of each representative experiment. P-value calculated 
based on ANOVA: 0.1234 (ns), 0.0332 (*), 0.0021 (**), 0.0002 (***) and < 
0.0001(****). 
 
7.2.2 Functional impact of reported DDR1 mutations in MCF10A benign 
breast epithelial cells 
DDR1 amplification is commonly observed in various types of cancer, 
including metastatic breast cancer (~14%) [199, 200]. Recently, a large genomic 
analysis of ER-positive breast cancer patients identified uncommon mutations in 
DDR1 that were associated with early relapse and cancer recurrence [198]. To 
understand the differential effects of these mutations, we transduced MCF10A cells 
with lentivirus constructs expressing WT and the various DDR1 mutants. Compared 
with parental MCF10A cells (with empty vector), the MCF10A cells stably expressing 
wild-type DDR1 or DDR1 with mutations mostly in the kinase domain exhibited 
modestly higher levels of cell growth. However, in this screen, mutations did not 
significantly enhance growth beyond that seen with wild-type DDR1 overexpression 
(Figure 25A). Immunoblot analysis of MCF10A cells overexpressing wild-type DDR1 
as well as several DDR1 mutants revealed a differential increase in RB 












Figure 25. Functional impact of reported DDR1 mutations in MCF10A benign 
breast epithelial cells. A) MCF10A cells were transduced with lentivirus constructs 
expressing WT (wild-type) and various DDR1 mutations. Following puromycin 
selection, the survival was analyzed with SRB assay after 72 hours. B) Western blot 
validation of DDR1, RB phosphorylation (serine 807/811) and c-Myc in MCF10A 




7.2.3 Sensitivity to DDR1 inhibitor 7rh in a panel of breast cancer cell lines 
with different ER statuses and PI3K pathway mutations 
To assess the sensitivity of other breast cancer cell lines to 7rh, the IC50 in a 
panel of ER-positive and ER-negative cell lines with differential PI3K pathway 
mutations was determined (Figure 26). The results showed that ER-positive cell 
lines are more sensitive to 7rh than are ER-negative cell lines, perhaps due to higher 
expression of DDR1 as revealed in earlier TCGA and METABRIC dataset analyses 















Figure 26. Sensitivity to DDR1 inhibitor 7rh in a panel of breast cancer cell 
lines with different ER statuses and PI3K pathway mutations. Bar chart showing 
7rh sensitivity in a panel of ER-positive and ER-negative breast cancer cell lines with 
differential activation of PI3K pathway. All data mean ± SD are indicated using 
triplicate samples of each representative experiment. P-value calculated based on 




Our data showed that the ectopic overexpression of DDR1 in MCF10A benign 
breast epithelial cells significantly increased cell growth and proliferation and 
induced anchorage-independent colony formation. Further, we demonstrated that 
MCF10A cells exhibited an increase in RB phosphorylation and c-Myc levels in 
response to DDR1 overexpression, suggesting a potential role for DDR1 in growth 
enhancement through induction of cell cycle. Interestingly, MCF10A cells 
overexpressing DDR1 were markedly more sensitivity to 7rh than were parental cells 
but were less responsive to palbociclib, indicating the involvement of DDR1 in 
attenuating palbociclib efficacy. The addition of 7rh inhibitor augmented palbociclib 
sensitivity in DDR1-overexpressing MCF10A cells, whereas no change was 
observed in parental cells. Taken together, these results support DDR1’s pro-
survival function and its role in alleviating palbociclib sensitivity.  
MCF10A cells stably expressing DDR1 mutations detected in clinical samples 
exhibited distinct proliferation rates and various levels of phosphorylated RB and c-
Myc, compared with parental MCF10A (with empty vector). As anticipated, DDR1 
protein level increased in all MCF10A cell lines harboring wild-type DDR1 as well as 
mutated DDR1, except the cells expressing Q92Nfs or W443Cfs frame-shift 
mutations. The c-Myc oncogene has been shown to collaborate with E2F in inducing 
the expression of target genes involved in cell cycle progression [201]. Notably, 
elevated DDR1 level was consistent with increased c-Myc expression across the 
MCF10A cell lines expressing DDR1 mutations, while RB phosphorylation level 
showed differential alterations regardless of DDR1 expression (Figure 25B). It is 
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possible that DDR1 acts as an upstream mitogenic force to enhance c-Myc 
activation and promote cell cycle. In mammalian cells, c-Myc transcriptional activity 
can positively regulate cyclin E, inducing G1-S transition in parallel with the pRB/E2F 
pathway during cell cycle progression [202]. Nevertheless, elevated DDR1 and c-
Myc levels do not necessarily confer growth advantage. The expression of R93Q 
and M311V mutations induced and suppressed the proliferation of MCF10A cell 
lines respectively (Figure 25A), while both equally increased DDR1 and c-Myc 
protein levels (Figure 25B), compared with parental cells. The incomparable 
functional impacts of these mutations might be attributed to their distinct locations in 
the DDR1 domain. The R93Q mutation maps to ligand-binding domain (DS domain) 
responsible for receptor activation, whereas M311V is located on the less critical 
DS-like region of DDR1. After all, more investigations are required to determine the 
functional consequences of DDR1 mutations in breast cancer progression. 
 The TCGA and METABRIC dataset analyses described above revealed that 
the ER-positive breast cancer subtype has a higher DDR1 expression (Figures 15A 
and B). Similarly, ER-positive cell lines displayed more sensitivity to 7rh-induced 
DDR1 inhibition (Figure 26). ER-positive cell lines without PI3K pathway alterations 
were more responsive to 7rh than were ER-negative cell lines having PIK3CA 
mutations. Meanwhile, PI3K pathway mutations provided more efficacy toward 7rh-
induced DDR1 inhibition. These observations suggest a potential correlation 
between ER, DDR1, and PI3K pathway mutations that could enhance the targeted 
therapy of DDR1 tyrosine kinase in breast cancer. 
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8.1 INTRODUCTION 
As described earlier, endocrine therapy in combination with the selective 
CDK4/6 inhibitor palbociclib is the standard-of-care treatment for ER-positive, HER2-
negative metastatic breast cancer. Despite the initial efficacy of this therapy, patients 
eventually acquire resistance to palbociclib, thus attenuating its effectiveness. 
Considering the potential role of DDR1 inhibition in preventing palbociclib resistance 
induced by the frequently occurring PIK3CA mutations, it is crucial to explore the 
DDR1 molecular mechanism underlying cell cycle progression. Understanding the 
molecular and functional consequences of DDR1 activation will help in designing 
DDR1 targeted therapy to improve the efficacy of palbociclib in ER-positive, PIK3CA 
mutated advanced metastatic breast cancer. 
To examine the synergistic effect of combined DDR1 and CDK4/6 inhibitions 
on improving palbociclib efficacy limited by PIK3CA mutation, we established MCF7-
PIK3CA xenograft tumors in NOD scid gamma (NSG) mice. This model has the 
advantage of mimicking tumor microenvironment and physiological conditions. 
RPPA analysis is a proteomic approach for molecular characterization of cultured 
cell lines and tissues. The use of RPPA can reveal variations in protein expression 
between samples in a short time. Exploring the expression of a large number of 
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proteins in xenograft tumors treated with single-agent 7rh or palbociclib and their 
combination can help identify novel proteins critical for specific treatment response. 
The differential expressions of relevant as well as novel proteins in different 
treatment groups will help explain the molecular signaling responsible for the 
synergistic effect in the dual treatment of 7rh and palbociclib.   
8.2  RESULTS 
8.2.1 DDR1 inhibitor 7rh inhibits the growth of PIK3CA xenograft tumors and 
synergizes with palbociclib in vivo 
To validate the synthetic lethality induced by 7rh and palbociclib in vivo, 
MCF7-PIK3CA xenograft tumors were established in NSG mice supplemented with 
17β-estradiol pellets. Treatment with single-agent 7rh or palbociclib inhibited tumor 
growth by 31% and 38%, respectively (7rh vs. vehicle, P=0.013; palbociclib vs. 
vehicle, P=0.0001). Combination treatment significantly inhibited tumor growth by 
49% compared with vehicle (P<0.0001) and each drug alone (combination vs. 7rh, 
P=0.0001; combination vs. palbociclib, P<0.0004) (Figure 27A). These results 
indicate that the combination of palbociclib and 7rh improved antitumor efficacy in 
vivo. The mice that received 7rh plus palbociclib exhibited no significant change in 
body weight, suggesting that this combination is well-tolerated. 
Immunohistochemical staining revealed a lower level of proliferation marker Ki67 in 
palbociclib-treated tumors compared with controls (P=0.0001), and the addition of 
7rh further decreased the proliferation rate (P<0.0001) (Figures 27B and C). Tumors 
treated with either 7rh alone or palbociclib plus 7rh expressed a higher level of P21 
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than did controls or tumors treated with palbociclib alone (Figure 27D). 7rh 
significantly increased P21 expression H-scores in tumors as a single treatment 
(P=0.048) and in combination with palbociclib (P=0.026) (Figure 27E). 
 
                  
 





      
 
Figure 27. Dual inhibition of DDR1 and CDK4/6 decreases the tumor growth of 
PIK3CA-mutated cells in vivo. A) NSG mice supplemented with 17β-estradiol 
pellets were injected with MCF7-PIK3CA cells (10x106) suspended in matrigel and 
divided into the indicated treatment groups (n=5). The tumor sizes were measured 
every 4 days for 36 days (the end of treatment). B-E) Representative images and H-
scores of IHC staining for Ki67 and P21 expression in MCF7-PIK3CA xenograft 
tumors. Scale bars are 100 μm. 
 
8.2.2 DDR1 inhibition induces cell cycle arrest and synergizes with 
palbociclib to suppress tumor growth in vivo 
To profile cell signaling changes in response to the treatment combination of 
palbociclib and 7rh, we performed RPPA analysis of PIK3CA tumor xenografts. 
Several altered key signaling molecules in cancer were analyzed by using Student’s 
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t-test (Figure 28A). Consistent with the in vitro results, several cell signaling–related 
proteins (PLK1, pRB-S807/811, cyclin B1, and FoxM1) were significantly 
downregulated in response to the combination of palbociclib plus 7rh (Figure 28B). 
Together, these results indicate that DDR1 inhibition induces cell cycle arrest and 










                      
Figure 28. DDR1 inhibition induces cell cycle arrest and synergizes with 
palbociclib to suppress tumor growth in vivo. A) The heat-map of selected 
signaling proteins revealed by the RPPA analysis of MCF7-PIK3CA tumor tissues in 
different treatment groups. B) RPPA statistical analysis of the cell-cycle associated 
proteins. All data mean ± SD are indicated using triplicate samples of each 
representative experiment. P-value calculated based on ANOVA: 0.1234 (ns), 







These results indicate that the combination of palbociclib and 7rh significantly 
enhances the treatment’s antitumor efficacy in vivo, compared with either of these 
agents used as a single treatment. RPPA analysis of PIK3CA tumor xenografts 
showed that PLK1, pRB-S807/811, cyclin B1, and FoxM1 proteins were 
considerably downregulated in response to the combination of palbociclib and 7rh 
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(Figure 28B). Consistent with the in vitro results, levels of PLK1 protein (master 
regulator of the G2-M phase) and cyclin B1 decreased significantly in response to 
combined treatment, compared with single-agent treatment and controls (palbociclib 
plus 7rh vs palbociclib alone: P=0.01). A recent next-generation transcriptomic study 
in ER-positive palbociclib-sensitive and palbociclib-resistant MCF7 cells identified 
PLK1 deregulation as a novel potential mechanism of resistance to palbociclib [203]. 
Importantly, upregulation of PLK1 has been reported in tamoxifen-resistant ER-
positive breast cancer cells, suggesting that PLK1 inhibition suppresses cell 
proliferation and in vivo tumor growth [204]. Accordingly, PLK1 may play a major role 
in driving palbociclib resistance in ER-positive, PIK3CA-mutated breast cancer.  
Together, these results show that DDR1 inhibition induces cell cycle arrest 
and synergizes with a low dose of palbociclib, potentially through targeting PLK1 and 
cyclin B1 to suppress tumor growth in vivo. Our data suggest that DDR1 targeted 
therapy combined with CDK4/6 inhibition can augment palbociclib efficacy in ER-
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9.1 DISCUSSION 
Clinical advances in the last decades have significantly improved outcomes 
for patients with HR-positive breast cancer. FDA-approved CDK4/6 inhibitors have 
doubled the time to disease progression when they are added to endocrine 
treatment for ER-positive, HER2-negative advanced breast cancer. Even so, intrinsic 
or acquired resistance to these therapeutic agents appears to be inevitable, and 
understanding the mechanisms underlying this condition has proven challenging. 
Initial studies implicated PI3K/AKT signaling, the most common activated oncogenic 
pathway in ER-positive breast cancer, in the blocking of apoptosis. However, more 
recent evidence has also associated this pathway with the induction of cell cycle 
progression. The pathway has been shown to be upregulated in response to chronic 
exposure to CDK4/6 inhibitors, which in turn upregulates cyclin D1 to drive cell cycle 
progression in the absence of CDK4 and 6 [116]. Further, AKT, as the primary 
mediator of PI3K signaling, regulates the stability of cyclin-dependent kinase 
inhibitors p21Cip1 and p27Waf1, leading to DNA synthesis and increased cellular 
proliferation [205, 206].   
In this series of studies, we performed a human kinome shRNA library 
screening with ER-positive HER2-negative isogenic MCF7 breast cell lines to 
identify the genes that, when targeted, sensitize PIK3CA and AKT1 mutant cells to 
CDK4/6 inhibitors. The use of isogenic cell lines is a complementary approach to 
study the influence of genotype on drug sensitivity, as it eliminates the effect of other 
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alterations that could impact sensitivity. To date, none of the identified human breast 
cancer cell lines have an AKT1 mutation. Consequently, the use of the AKT1 knock-
in model helps us better assess the effects of this mutation. 
This screening revealed 25–35 palbociclib synthetic lethality hits. Although 
most of the candidate genes were involved in a variety of cellular growth and signal 
transduction pathways, the screening revealed DDR1 as the only novel target that 
confirmed synthetic lethal interaction with palbociclib in PIK3CA and AKT1 mutant 
cell lines. To date, the role of DDR1 in cancer biology has been relatively unknown; 
however, a previous report suggested that DDR1 promotes invasion in breast 
carcinoma and enhances the chemoresistance [207]. A recent study revealed that in 
non-small cell lung cancer, co-inhibition of DDR1 and cell-surface transmembrane 
4 L six family member 1 (TM4SF1) causes synergistic reduction of cell proliferation 
and tumor growth [208]. Moreover, dual pharmacological inhibition of DDR1 (with 
7rh) and Notch pathways hampers the growth of KRAS-mutant lung 
adenocarcinoma [165]. 
Although we found that ER-positive breast cancers with PIK3CA and AKT1 
mutations are less sensitive to palbociclib monotherapy in vitro in an isogenic panel, 
this association has not been reported clinically. AKT1 mutations are rare, found in 
only 4% of breast cancers, and to date the specific efficacy of CDK4/6 inhibitors has 
not been reported in this genotype. PIK3CA mutations are relatively common in HR-
positive breast cancer, yet there is no clear association between PIK3CA mutational 
status and resistance to CDK4/6 inhibitors in clinical trials examining the 
combination of endocrine therapy with CDK4/6 inhibitors. In the Phase III 
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MONALEESA-2 trial (NCT 01958021), the combination of the CDK4/6 inhibitor 
ribociclib plus letrozole was compared with placebo plus letrozole for first-line 
treatment in postmenopausal women with HR-positive, HER2-negative advanced 
breast cancer [104]. The benefit from ribociclib was maintained irrespective of 
PIK3CA mutation status. Similarly, in the Phase III PALOMA-3 clinical trial, 
premenopausal and postmenopausal women with HR-positive, HER2-negative 
metastatic breast cancer were randomized to fulvestrant in combination with either 
palbociclib or placebo; PIK3CA mutations were detected in the plasma DNA of the 
129 (33%) of 395 patients for whom these data were available; PIK3CA status did 
not significantly affect treatment response [97]. Tumor PIK3CA mutation rates were 
lower among long-term responders in both arms [209]. Circulating tumor DNA 
sequencing performed at baseline and end-of-treatment for 195 patients in the 
PALOMA-3 trial showed that new driver mutations emerged in PIK3CA (p=0.00069) 
and ESR1 after treatment in both arms [210]. Taken together, these data suggest 
that further research is needed to determine the impact of PIK3CA/AKT1 mutations 
on the efficacy of CDK4/6 inhibitors as monotherapy. Emerging data already 
indicates that PIK3CA mutations may underlie acquired resistance to fulvestrant plus 
palbociclib, possibly by driving fulvestrant resistance. Accordingly, downregulation of 
ER to mirror dual endocrine and CDK4/6 inhibitor therapies might be able to better 
model this approach. 
We found that DDR1 genomic suppression and 7rh inhibition alone markedly 
reduce cell proliferation, regardless of PI3K pathway activation, and caused tumor 
regression in vivo. We also showed that co-inhibition of CDK4/6 and DDR1 in 
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PIK3CA and AKT1 mutant cells caused a synergistic decrease in the cell population 
of S and G2/M phases, accompanied by a reduction in RB phosphorylation and 
cyclin E2. Although these results indicate that the DDR1 inhibitor 7rh induces cell 
cycle arrest, the mechanism of this synthetic lethal interaction is unknown. A study in 
a cohort of TCGA breast cancer patients showed that luminal A and B tumors 
express significantly higher levels of DDR1 mRNA, compared with basal-like breast 
tumors [171]. This was consistent with our western blot data, in which we detected a 
higher DDR1 expression level in ER-positive breast cancer cell lines. It suggests a 
potential correlation between DDR1 expression and the hormone receptor status of 
the tumor. 
Apart from co-expression with ER, DDR1 is involved in regulating and 
interacting with various growth factor pathways. It has been predicted that the close 
proximity of RTKs and activated DDR1 acts as a scaffold molecule for PI3K 
signaling[211]. Similarly, DDR1 association with an AKT1-protein-complex assembly 
has been identified as inducing pro-survival AKT signaling [212]. Recently, a novel 
functional cross-talk between DDR1 and insulin-like growth factor 1R through the 
PI3K/AKT/miR-199 circuit has been revealed in breast cancer [143]. The PI3K 
pathway mediates cell cycle progression through cap-dependent mRNA translation 
of cyclin-dependent kinases that phosphorylate RB, resulting in its dissociation from 
E2F [213]. Increased transcriptional activity mediated by the free E2F induced the 
transcription of cell cycle key regulators, including FoxM1 [214]. As a result, it is 
possible that DDR1 inhibition via 7rh attenuates the PI3K/AKT-mediated induction of 
cell cycle. Therefore, we can speculate that cooperative regulation of cell cycle 
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pathway induced by DDR1 and PI3K/AKT signaling in the context of ER-positivity 
might be responsible for the therapeutic interaction of palbociclib and 7rh. In 
summary, we have evaluated a novel combination of CDK4/6 and DDR1 inhibition in 
PIK3CA/AKT1 mutant ER-positive breast cancer that provides synergistic inhibition 
of cell cycle and suppression of tumor growth. 
9.2 FUTURE DIRECTIONS 
CDK4/6 inhibitors in combination with endocrine therapy has become the 
standard of care for ER-positive, HER2-negative advanced metastatic breast cancer. 
The FDA-approved CDK4/6 inhibitor palbociclib doubles PFS when added to 
endocrine treatment for ER-positive, HER2-negative advanced breast cancer. In the 
studies discussed here, we found that ER-positive breast cancer cell lines with 
PIK3CA or AKT1 mutations are less sensitive to palbociclib monotherapy. 
Additionally, this association needs to be examined in response to estrogen 
depletion or ER degradation to imitate CDK4/6 inhibitor and endocrine combination 
therapy used in the clinic. Recently, analysis of tumor DNA from patients enrolled in 
the PALOMA-3 trial identified PIK3CA-activating mutations as a driver of resistance 
to palbociclib [215]. Determining the sensitivity of PIK3CA or AKT1 mutated cell lines 
to endocrine treatments (e.g., tamoxifen, fulvestrant) alone and in combination with 
palbociclib will mirror a more clinically relevant approach. 
Our data showed that targeted therapy combining DDR1 with CDK4/6 
inhibition augments palbociclib efficacy in PIK3CA-mutated, ER-positive breast 
cancer in vitro and in vivo. However, clonal evolutions and the absence of stromal 
interaction in cultured cells may affect the therapeutic evaluation of targeted 
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inhibitors. In addition, intra-tumor heterogeneity and the potential alterations 
accumulating during tumor development represent limitations that impede the 
identification of potent oncogenic targets. Therefore, future studies using patient-
derived xenograft tumor models are required to further assess the therapeutic 
efficacy of DDR1 and CDK4/6 co-inhibition. We used MCF10A cell lines as ectopic 
overexpression models to evaluate the functional consequences of various DDR1 
mutations. These models lack ER expression and the required PI3K pathway-
activated genetic background to study the pro-survival interaction between DDR1 
and PI3K signaling, but may be practical for assessing the transformational ability of 
DDR1 as an oncogene. Nonetheless, to better understand the molecular 
mechanisms induced by DDR1 wild-type or mutations, an inducible ectopic 
expression system that can substantially recapitulate DDR1 endogenous activity is 
essential. 
Higher DDR1 mRNA and protein expressions were observed in ER-positive 
cell lines with mutated PIK3CA or AKT1 than in wild-type cells (Figures 18A and C). 
Meanwhile, the analysis of TCGA and METABRIC data from patients with breast 
cancer revealed a higher DDR1 expression in patients with HR-positive breast 
cancer than in patients with triple-negative breast cancer (Figures 16A and B). The 
tendency toward co-occurrence of high DDR1 expression and PIK3CA or AKT 
mutations in ER-positive patients was not consistent across different datasets 
(Figures 16C–E), which may suggest the association of DDR1 with other potential 
mutations to enhance tumor survival. Intriguingly, a recent study revealed that lung 
adenocarcinoma tumors and cell lines with EGFR mutations expressed higher DDR1 
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level [165]. Therefore, investigating the co-occurrence of DDR1 with alternative 
driver oncogenes can identify a broader group of ER-positive breast cancer patients 
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